<SEC-DOCUMENT>0001144204-15-024337.txt : 20150422
<SEC-HEADER>0001144204-15-024337.hdr.sgml : 20150422
<ACCEPTANCE-DATETIME>20150422163707
ACCESSION NUMBER:		0001144204-15-024337
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150422
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150422
DATE AS OF CHANGE:		20150422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		15786031

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v407883_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
DC 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CURRENT
REPORT Pursuant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>to
Section 13 or 15(d) of the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Securities
Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date
of earliest event reported): <U>April 22, 2015</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding: 0; font-size: 10pt; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SANGAMO BIOSCIENCES, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exact Name of Registrant as Specified in Its Charter)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; font-size: 10pt; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Delaware</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State or Other Jurisdiction of Incorporation)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>000-30171</B></FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>68-0359556</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(IRS Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>501 Canal Blvd, Suite A100</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Richmond, California 94804</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(510) 970-6000</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Registrant&rsquo;s Telephone Number, Including Area Code)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: center; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Former Name or Former Address, if Changed Since Last Report)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 2.02.&nbsp;&nbsp;</B></FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Results of Operations and Financial Condition. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 22, 2015,
Sangamo BioSciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2015. A copy
of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 9.01 </B></FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Exhibits. The following material is
filed as an exhibit to this Current Report on Form 8-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exhibit No.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release Issued April 22, 2015.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DATE: April 22, 2015</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SANGAMO BIOSCIENCES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 4%; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 40%; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ EDWARD O. LANPHIER II</FONT></TD>
    <TD STYLE="width: 1%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Edward O. Lanphier II</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President, Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v407883_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head><META content="text/html; charset=utf-8"></META></head><body style="font-size:10pt;font-family:Arial;color:black;"><div style="width:100%;margin-left:10pt">
<p style="text-align:center"><b>Sangamo BioSciences Reports First Quarter 2015 Financial Results</b></p></div><div style="width:100%;margin-left:10pt;"><div style="margin:0;margin-top:16pt;"><p>RICHMOND, Calif., April 22, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its first quarter 2015 financial results and accomplishments.</p><div style="TEXT-ALIGN: left; WIDTH: 100%" id="prni_dvprnejpg6305left"><img src="sf35903logo.jpg" id="prnejpg6305left" title="Sangamo BioSciences, Inc." border="0" alt="Sangamo BioSciences, Inc." align="middle"></div><p>For the first quarter ended March 31, 2015, Sangamo reported a consolidated net loss of $5.3 million, or $0.08 per share, compared to a net loss of $7.6 million, or $0.12 per share, for the same period in 2014. As of March 31, 2015, the Company had cash, cash equivalents, marketable securities and interest
receivable of $226.1 million.</p><p>Revenues for the first quarter of 2015 were $13.5 million, compared to $8.1 million for the same period in 2014. First quarter 2015 revenues were generated from the Company&#39;s collaboration agreements with Shire International GmbH (Shire), Biogen Inc. (Biogen), and Sigma-Aldrich Corporation (Sigma), enabling technology agreements and research grants. The revenues recognized for the first quarter of 2015 consisted of $12.7 million in collaboration and enabling technology agreements and $0.8 million in research grants, compared to $7.6 million and $0.5 million, respectively, for the same period in 2014. The increase in collaboration agreement revenues was primarily due to increases in revenues under the Company&#39;s collaboration agreements with Sigma and Biogen.</p><p>In the first quarter of 2015, Sangamo recognized $4.5 million of revenues related
to research services performed under the collaboration agreement with Shire, and $1.5 million of revenues related to research services performed under the collaboration agreement with Biogen. In addition, pursuant to the agreements entered into with Shire in January 2012 and Biogen in January 2014, Sangamo received upfront payments of $13.0 million and $20.0 million, respectively. These payments are being recognized as revenue on a straight-line basis over the initial six-year research term for Shire and approximately 40 months for Biogen. The Company recognized $0.5 million of the Shire upfront payment and $1.5 million of the Biogen upfront payment as revenue for the first quarter of 2015.</p><p>Research and development expenses were $15.0 million for the first quarter of 2015, compared to $12.1 million for the same period in 2014. The increase was primarily due to increases in
manufacturing expenses, external research expenses associated with our preclinical programs, and personnel-related expenses, including stock-based compensation. General and administrative expenses were $4.7 million for the first quarter of 2015, compared to $3.6 million for the same period in 2014. The increase was primarily due to increases in personnel-related expenses, including stock-based compensation, as well as increases in legal and professional services.</p><p>Total operating expenses for the first quarter of 2015 were $19.7 million, compared to $15.7 million for the same period in 2014.</p><p><b>Recent Events</b></p><ul type="disc">
<li><b>Presentation of New Clinical Data at CROI 2015 from Phase 1/2 SB-728-1101 clinical trial of ZFP Therapeutic Designed to Provide Functional Control of HIV.&#160; </b>In February 2015&#160;Sangamo presented new clinical data from its SB-728-T program for the potential functional cure of HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections (CROI 2015). The data demonstrated that Cytoxan preconditioning combined with treatment with a CD4/CD8 zinc finger nuclease (ZFN)-modified T-cell product in (Cohort 3*) reduced viral load to below the limit of quantification in one of three subjects, and delayed onset of viremia for over 8 weeks, from the start of treatment interruption (TI), in another subject. Currently, all three patients from the cohort are undergoing TI. </li>
<li><b>FDA Acceptance of IND to Initiate Clinical Trial of ZFP Therapeutic Approach for Beta-thalassemia.</b> In February 2015 Sangamo announced that the Investigational New Drug (IND) application for SB-BCLmR-HSPC, designed to provide a one-time, long-lasting treatment for beta-thalassemia, and developed in collaboration with Biogen, was accepted by the U.S. Food and Drug Administration (FDA) and is active. The IND enables Sangamo to initiate a Phase 1/2 clinical trial of the ZFP Therapeutic in transfusion-dependent patients with beta-thalassemia major. The trial will assess the safety and tolerability, and measures of efficacy of this approach. In May 2013 Sangamo was awarded a $6.4 million Strategic Partnership Award from CIRM, providing matching funds for preclinical work to support the IND application and Phase 1/2 clinical trial to develop this ZFP Therapeutic. The trial will be
carried out at multiple centers, including UCSF Benioff Children&#39;s Hospital Oakland. </li>
<li><b>FDA Acceptance of IND Application to Initiate a Phase 1 Clinical Trial of ZFP Therapeutic approach for HIV in Hematopoietic Stem Progenitor Cells (HSPCs). </b>In February 2015 Sangamo announced that subsequent to the FDA&#39;s recent acceptance of the IND application, Sangamo and its collaborators at City of Hope expect to initiate a Phase 1 clinical trial of ZFN-modified HSPCs. </li>
<li><b>Completion and closure of CERE-110 trial in Alzheimer&#39;s disease. &#160;</b>Data from a clinical trial of CERE-110 in subjects with Alzheimer&#39;s disease (AD), acquired as part of the acquisition of Ceregene in 2013, demonstrated that direct administration into the brain of AAV encoding the nerve growth factor gene (AAV-NGF) in subjects with AD&#160;was safe and well tolerated. As previously stated, Sangamo will not pursue this approach for potential treatment of AD and has terminated the CERE-110 program. </li>
<li><b>Presentation of Preclinical Data at 11<sup>th</sup> Annual WORLDSymposium&#8482; Meeting Supporting IVPRP Approach for the Treatment of LSDs. </b>In February 2015 the Company presented preclinical data from its In Vivo Protein Replacement Platform (IVPRP) for the development of ZFP Therapeutics for the potential cure of lysosomal storage disorders (LSDs), at the WORLDSymposium&#8482; 2015 Meeting. The data demonstrated that genes encoding functional human enzymes, defective in the LSDs Hunter, Hurler and Gaucher syndromes, could be inserted into the albumin locus of normal mice. Following ZFN-mediated genome editing, robust levels of protein expression were observed in the liver, blood plasma and spleen, consistent with the effective production, secretion and uptake of the functional therapeutic proteins by other cells and tissues of the body. Furthermore, elevated enzyme
activity in the blood plasma was sustained over the course of the two month study. </li>
<li><b>In-Licensing of mRNA Delivery Technology and Expansion of Therapeutic Pipeline Opportunities for In Vivo ZFN Platform.</b> In January 2015 Sangamo in-licensed nanoparticle technology enabling systemic mRNA delivery of ZFNs. Sangamo is developing applications of this technology to enable repeat-dosing of ZFNs <i>in vivo,</i> providing the opportunity to &#34;dose to effect.&#34; The ability to re-dose could expand applications of ZFN-mediated <i>in vivo</i> genome editing to numerous, well-established therapeutic &#34;knock-out&#34; targets in the liver, such as PCSK9, a gene that regulates LDL cholesterol associated with cardiovascular disease.</li></ul><p><b>Financial Guidance for 2015
<br /></b><b>The Company reiterates its earlier guidance as follows:</b></p><ul type="disc">
<li><b>Cash and Investments:</b> Sangamo expects that its cash, cash equivalents and marketable securities will be at least $180 million at the end of 2015, inclusive of research funding and certain milestone payments from Shire and Biogen but exclusive of funds arising from any additional new collaborations or partnerships, equity financings or other new sources. </li>
<li><b>Revenues: </b>Sangamo expects that revenues will be in the range of $60 million to $70 million for 2015, inclusive of research funding and certain milestone payments from Shire and Biogen. </li>
<li><b>Operating Expenses:</b> Sangamo expects that operating expenses will be in the range of $100 million to $110 million for 2015. </li></ul><p><b>Conference Call
<br /></b>Sangamo will host a conference call today, April 22, 2015, at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under &#34;Events and Presentations&#34; http://investor.sangamo.com/events.cfm.  A replay of the webcast will also be available for two weeks after the call. During the conference call, the Company will review these results, discuss other business matters and provide guidance with respect to 2015.</p><p>The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 20895051.  For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00
p.m. ET on April 22, 2015 to 11:59 p.m. ET on April 29, 2015. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 20895051.</p><p><b>About Sangamo</b></p><p>Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures<sup>TM</sup> for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has clinical stage programs to evaluate the safety and efficacy of novel ZFP Therapeutics<sup>&#174;</sup> for the treatment of HIV/AIDS (SB-728) and beta-thalassemia (SB-BCLmR-HSPC). Sangamo&#39;s other therapeutic programs are focused on monogenic and rare diseases. The Company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for
hemophilia, Huntington&#39;s disease and other monogenic diseases, and with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company&#39;s website at www.sangamo.com.</p><p><i>ZFP Therapeutic</i><i><sup>&#174;</sup></i><i> is a registered trademark of Sangamo BioSciences, Inc.</i></p><p><i>This press release contains forward-looking statements regarding Sangamo&#39;s current expectations.  These forward looking statements include, without limitation, references to the initiation of clinical trials, anticipated cash and investment balance, operating expenses, revenue and potential milestone and royalty payments under Sangamo&#39;s
agreements with Shire, Biogen and Sigma, the research and development of </i><i>ZFNs and ZFP TFs, clinical trials and therapeutic applications of Sangamo&#39;s ZFP technology platform and achievement of research milestones and objectives under collaboration agreements with Shire and Biogen</i><i>. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships. Further, there can be
no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo&#39;s operations and business environments. These risks and uncertainties are described more fully in Sangamo&#39;s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.</i></p><p>
<br /></p><div>
<div><table style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt" border="0" cellspacing="0" cellpadding="0"><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>SELECTED CONSOLIDATED FINANCIAL DATA</b></font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">(in thousands, except per share data)</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>Statement of Operations Data:</b></font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td colspan="3" style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">&#160;Three Months Ended&#160;&#160;</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td colspan="3" style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">&#160;March 31,&#160;</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">2015</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">2014</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Revenues:</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">&#160; Collaboration agreements</font></font></p></td><td nowrap="nowrap" style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">$ &#160; &#160; &#160; &#160; &#160;12,671</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td nowrap="nowrap" style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;7,568</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">&#160; Research grants</font></font></p></td><td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom;
BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">820</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">548</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">&#160;&#160;&#160; Total revenues</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">13,491</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">8,116</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Operating expenses:</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; BORDER-LEFT: 1pt; PADDING-LEFT: 12px; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Research and development</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">14,980</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">12,083</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; BORDER-LEFT: 1pt; PADDING-LEFT: 12px; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">General and administrative</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">4,732</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">3,644</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; BORDER-LEFT: 1pt; PADDING-LEFT: 24px; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Total operating expenses</font></font></p></td><td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: black 0.5pt solid; BORDER-RIGHT: 1pt"><p style="MARGIN:
0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">19,712</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: black 0.5pt solid; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">15,727</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Loss from operations</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN:
0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">(6,221)</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">(7,611)</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Interest and other income, net</font></font></p></td><td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">154</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">39</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Loss before taxes</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">(6,067)</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">(7,572)</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Provision income tax</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">748</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">-</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Net loss</font></font></p></td><td nowrap="nowrap" style="BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: black 0.5pt solid; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">$ &#160; &#160; &#160; &#160; &#160;(5,319)</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td nowrap="nowrap" style="BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: black 0.5pt solid; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;(7,572)</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Basic and diluted net loss per common share</font></font></p></td><td nowrap="nowrap" style="BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; BORDER-LEFT:
1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: black 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">$ &#160; &#160; &#160; &#160; &#160; &#160;(0.08)</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td nowrap="nowrap" style="BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: black 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;(0.12)</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Shares used in computing basic and diluted net loss per </font><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">common share</font></font></p></td><td
style="BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">69,283</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: black 2pt double; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">63,199</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><u>March 31, 2015</u></font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: center; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><u>December 31, 2014</u></font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>SELECTED BALANCE SHEET DATA</b></font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: left; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Cash, cash equivalents, marketable securities and interest receivable</font></font></p></td><td nowrap="nowrap" style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">$ &#160; &#160; &#160; &#160;226,123</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt;
VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td nowrap="nowrap" style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">$ &#160; &#160; &#160; &#160; &#160; &#160; &#160;226,645</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Total assets</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p
style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">238,505</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">243,212</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Total stockholders&#39; equity</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">207,488</font></font></p></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; TEXT-ALIGN: right; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">206,633</font></font></p></td></tr></table></div></div><p> </p><p>Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO </p><p> </p>
<br /><br /><p>CONTACT: Sangamo BioSciences, Inc., Elizabeth Wolffe, Ph.D., (510) 970-6000, x271 OR Varant Shirvanian, (510) 970-6000, x205</p></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>sf35903logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sf35903logo.jpg
M_]C_X``02D9)1@`!`@```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`0$"`0$!`@("`@("`@("`0("`@("`@("`@+_
MVP!#`0$!`0$!`0$!`0$"`0$!`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@("`@("`@("`@("`@("`@("`@+_P``1"`!;`9`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBF[N,X
M/^?Z5%).$&0C.><A2,C@D=3SR`/QI*2<^17<O1V^^UOQ)<HI7<DE9O731:[;
MD]0.X1CEL'TYSCZ`=./TJO-J$-M%)/=%;6WAA:>:>XFAAAABC7?+))+(X"1H
M@)9B<`#).*_*?]IW_@KA^SI\#6U;PWX,GNOB]\0[-+B$:-X5GMU\.6&I1EHA
M#KGBN5C#'"DBD/\`84O91CY8R>GT'#G"G$7&&84\LX;RNOFF-FTN6C#F4&]O
M:-VC!?XVCY'C/CS@_P`/\IGG7&.=T<FR^$7)2J2M.=K:0@DYREJM%&]VC]5)
MYX'C8&6(;D8IO4991MRRJ?OIR,D<#/6O%?B_^T9\%/@'I<>J?%KXC>&_!4<R
M*]I:ZG>*^KZA'YAA\RPT>QCEN+J`3*4+I"8TD95D="PS_,7I?_!07]MG]LOX
MW>`OA5X+\>K\*+#QUXKT_18M&\`PK;QZ?I[^3<:S=WVNWEE+>W8CT=-1E+2R
M+&3:NODJS)G[Q_X+C>&?"-G\#O@=K6I:?:ZEX_L_B39>&=-\8720CQ&?#\/A
M3Q'J>NQ>>L+*]E<ZA8Z1)/#POF-'(N"F#^O8?P'QN4\<\!\(<9YG'"U^,JC]
MM1P-JF(PU",G'GJ<RA!2YHSC[LYVY963L?SUC?I/Y=GGAKXD^(7`&1U:^`\/
M[06(S%<F'Q==J+]C2C2;Q7NJ49WDH4_>CK=Z_;/PE_X*6?LX?'WXL:9\(?A:
M/'WB/7=:BU&6+5$\(7%IHD=KIMG>W=S=7MW?743)9""UEV2B,J);JW4X+BOS
M:^*__!<GQCX=\4>(_"O@[]G'3]&D\/ZKJ^BW3_$;Q3?R:DL^E7L]E/'?>']&
MM+<:=>B>WDW1B]F3Y0ZNP8&MS_@A/\&--ET3XO\`QZU"QBGUF?68?ACX:N9@
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M3T?5E1FU:]LH9+MR&$=K!*9/WFTJ?Q!\:_\`!:G]K+6_$LFH>#['X=^"-`MK
M_P`FS\*3^%T\7.(9G#6]CXB\1:E>03WNIB,@?Z)!IJ2"1Y5#B+<?H#_@MYXC
M;PY_PS-\"=`*Z9X*\/>%=5\4KHMJP%J)[#^S?!_A4&-UP\-AHEKK$$2MU&IY
M)S\R_KW^QY^SO\)?!W[*GPFT*R\!>$[FU\7?"WP9KOC/[;HMC>-XKU?Q+X9T
MO6M6FUZ6[MI&U&)KV_G$8D8B&-$6-3M%?,X+#>''`G!.4>(7$G`5+B;$^(F.
MQSPF`G-K#8'+L-4480I/WKSFN:SDG+S5S[#,ZWC!XI>(F;>%W"'BC6X+P?A3
ME.7?VAF--2>*S',,73C4E*KR-6A&2]Y)\O+?>]C\2]5_X+B_&_4](\,Z)9?"
MSP=X8\66^OZ%+XP\6P:I>:U!J&@0WD;ZAI7A[PAJVC1IHU[>6_GK'+-J%RMO
ML+JK$K7ZP?M]_MT^,_V+H_AQJNF_!B#XE^#?&]SJ5AJ/B2^\92^&X=+U:S1;
MJTT"WB@\.7KFZN=*6XFCN)!Y(-JZ%-PP?YSOB/\`!+P[K'_!1G6?@3\.]"M[
M'PS??M!Z1HFFZ19@)9Z9H\6K6>HZU;0QP18@L+>"74B%5#LBBQ@D8K]*O^"U
M^NZWXZ^+G[+W[-WA^Y:%M9N;G6FM!EK<^(/&'B/2_!OA6^N(M^));.T@U@H"
M#D7S8#'BON>)O#?PQK<>^%>!R;AB.&R?B3`9GF^:81UYTU3P=6A2JX1*HI-I
MTDIQBG)Q6ME8_,^#O%KQEI^&7C9C\ZXXQ&8<0<.9OD^0Y3BHT</53QWUNIAL
M1&$9PC3^K5W.FZS<?;6:U>J/ISX6?\%K/V6O&)M;;QYHOC[X87\RPQW!U32K
M?Q+H4,T@*E+?6/#4DTTEL%R5>>RM2X!PO0']7?AI\4_AS\6O#%GXR^&_C/0O
M&GAC4$6.WUG0M1M[RU279%*]G<(C>9I^HQK)%YUM.L<T)=1+&K$"OY$U_96^
M%D?_``4JTS]E>Z?4+/X86OCGP]X8N5>]DDU75[.Q\$C69[2741L:WN=1N(52
M8J`(4G*P-E@1^FW_``5P^"'P@^"O[)'PUMOASX4TSX=IX5^,FGCPM;>%HCIT
M/V_7/#NK+XAO;R.!D^W7\NG:8))+AL7)DTZ.03*-Z/\``\?>%OAG/B?PZX>X
M.QF99+B>/Z5'$T8UHPQ>$H86M&4:3FVZ==3<H:PC)\L&G)\UXO\`2O"SQV\9
M(\'>*/&/B'@,LS_*O"NM6P=54)/"8ZKC,-*,*T8PIQEAI0BFH0E."E)QM&\;
M,_?4S(2Q4K,8"-T<9#O&Y(92^!E1Y9!YP",&F;8=I<DRN%VY7!EC1^=I&?O#
MGWP?I7\\O_!("X_;%\?)J/Q"UGXM:EKOP,T<:GX2@\*?$+Q%?>)]1U#Q1INE
M6CV8T6:ZTR6ZT;38)KJV%Q*-19-H,<5H9%D=]&P_X+(>/?A/\7O%'PL_:D^!
M^FZ?)X7U^\T+4]6^&VJZC>ZEHUQ;SM%:7\6@Z\7_`+=TJ6U-O<++#=VTHCN5
M/V7?N0?F^9^"?%M#BKB3A+A[%X;BO,.&:3K5UAKTVDM_<KRBTX)KVD5*35]V
M]#]FR;Z2O`]?@SA+C?BW!8W@C+.,ZTJ&&GBZ$*\%6H056-7VM#FYJ=2+?)-T
MX\RB[+37^A]>``.F!_*EKR/X/_'#X<_';P#H/Q*^&.NP^(_"GB&&=[&[A!BN
M([BSE2WU'3KVTGVR66IVMVSQ7$$JJ\4D+*P&!GU1;E6<H%;=UP1CY><MR/NY
MQS[^E?D%>G4PV+KX#$P=''864H5:4DU4IR@TI1G!^]!IM+WDC^A<'F&!S#!X
M;,,%BX8K`XV$*E&K"2E3JPJ*\)0DM)*2U5KNW0L45$)0>"I!YX)7/'ISS3T;
M<H;&,]L@XYQU!J6FMT=G]?\`#=UYK0=1112`B9E#@9^8+N`(."`3WSUS4)FB
M4A6D1"V0@<@%RHR=@/+8!R<9QU/'-%Q($=?D+E@<!0"2<'&<D<?X5_*'^U_^
MWG^TU^T#^TKK/P'_`&>_%?B/PEX:L/&FH?#?P?IG@*]DTC7O&WB72=4BT76=
M1U/Q#:SPSVUH;YRMO&DMLEK%`;EWFR\<7W_AUX;YQXD9ECL%E6(H9=@\KINO
MC,5BVXT,/27VY-)RLVG;2WNR['Y!XO\`C'D/@]DV!S+.L)7S;'9Q7^K8'!X2
M/-B,16M!^SA'=R7M(7LG\2LC^K;SX0'/FVYV`LX5U<H`"26522!@'KC^E/MY
M8WE949&(4YV[B05.",]!@D\=:_EQG_X)\_\`!5GPM82^)M#^//B&_P!4C@^U
MOI>F?M%>/+G4I-D3N(C%K<L-C-,%#;5$[*S``G&2/Z.?@98>+]#^$'PQL/B+
M?7.I^/+#X?>#['QE?7=P+NXNO%4.@Z;%XAN9+H,?M+R:LER[N223SWY?&W!&
M3\*4L!7R?CG+N,H8R34HX)XASHM)/]XJB5K]-'?5Z&?ACXD\5<<XG'X3B/PM
MSC@!X-*5.ICYT94Z]VK1C[./Q]7&_,D>QT5GOJ=M!")[MTLXRRKNN)(XTW,,
MA1(6VLV>.">0::=5M=OF(PECW*IEC9'B&\.59W1B(UPA)+8`R,GFO@'&2BIN
M+C!_:::731MJR>JT;/UYUZ2J*DY_OGM#5S?I!>\_N-*BJC7D:#+#:.#RRD[3
M@;B`>!DX/T)Z#--:]1!N92%`)=R\:K&.<;V9P`"!D'H?KQ4\RY%43YX2M9Q]
MZ][-<O+?FW6URI5*<4VYI*-KZ_#?K);Q2ZN5DNMB[167!K%E=,4MI8[AE!+>
M3-#(%8%E*$QR'Y@0,CMN&:MBXSD&)Q@`]CR1NV\'AL?YZ43?LW.,XN#IJ[3B
MT[--[-:Z)[7?3<FE7HUX\]"M&M#O"2DM'R[Q;5[M*U[_`"+-%9-WK>GV*AKJ
MXCMU9D1&N)(X$=Y&"K&)9&"^;U.S=O(4D*0,U,NH(REC%*B@'YG``R`K8SGC
M*NA!.`=W&<'%\D[1?)+EGK%V=GML[6>ZTW$\103JKVL>:@DYJ]W!2;2<DM4F
MT]7VU-"BJ9O(QD[6VCH^4V/DC8$;=\Q;)P.O'..,P7&K6=I&\EU(ENJ'#F:6
M%%7"[F+.T@"J.Y)`I14IS4(Q;G)72L[_`);^6_D.M7HX>FZU>K&E2BKN4FE'
MI]IZ/=;,TZ*JI=I)MV*S!^C`97&!D[AQQD9&<CTI);R&%6>4E`K%1G'S8[CG
MIGCFE]IQ6LEI9:N^FEE=WU6GF.56G"$JLIJ-*"3<F[1L]GS;-/NG8MT5G/JE
MM&&>1@D2KO>8R1[$7G#/\_RJ<'![[3Z4MMJ5K=H9+>19(@VWS%9"N3MQDJQV
MY+`#.,]JIQG&+G*#C".[::2]6U9>ER5B,.ZL*$<13E7J1YXP4XN<H_S**;;7
MFD:%%9DNK6,$@BEGC21ON1F2,2OR`"D1?++D]>GXD58^U`OL$;$%2R,&3Y\$
M9"KNR3R,\<=\<94E**C)Q:C.UG9ZWZK35:[K0(8C#U)5(4Z\)SI?$E.+<?)I
M.Z?DU?R+=%4_MB`J'1T+9.&Q\JC)W.0?E7CO].M01:O93RO!#*DDL7$B))$S
MIZ!D#[LD<@8R00>XJ;Z59*,I1HVYFHR:5]M4FGOK:]NHY5Z,948SJQISKJ\(
MS:A*2\HRLW]QIT5`LZEPF""Q8+DKSMQD@!O?GN.X%3T)IN233<=';H]_R->_
MD%%%%,`HHHH`J22[8\_*!@GYR0HP>I(!(Z]@2?3GG\__`-IK_@I'^S=^S#J,
MWAOQ7X@O_%/C6U7S;GP1X%L!K>NV*.I%N=8D^V1VVB%W*`+<3;V$@8QH#7D?
M_!4G]MC4?V7/A;8^#O`=['#\7_B?%>V6@3Q@RS^&O#-JAAUGQ*858-]M9I!:
MV!!W&[9Y$5FMMC?D5\.O^".'[3WQ;\%VGQ)\4>.?`WA37/&=M!XFMM'\73^*
M-:\2WT^M0QW@NO%NHP6LWEZE(K1NY7=*#<G[20RA#^]^&GAEP77RG"<:^+/$
M4N&.$\?6]GE]&//&MF"B^6K.+492IT:4O=E+E<G-QY597?\`*/C)XS^(.!XB
MQ/AQX(\*1XPXVRS"T\5FE>:A*AEU.O;V,)-SC&6(J*[C3;LEJT]C[P\2?M2:
M%_P51^%'COX#?`OQ+XT^!'Q0TNT'BN70/%LNG6FG_$GPQI\=[8ZAX7FUCPMJ
M=V;73FDU2*6X1WBD22W@D:"YL_M9M_P=^"G[-?BGQQ^U5X5_9C\:VUUX;UJX
M^(EUX3\;?9Y@M[I$&@2ZA?>)I].DVRI;W#Z7IUQ+:2IY\&ZYB=7N8"K/]8?L
MH>`/B7^QY_P4>^#WP]^)&G6NG:A=Z\?#<\]K="^T;7O#7CS0=4L=*U+2[T01
MB\T^XOWM`5VX\V)D?YH\+](_$&>#X)?\%L]%U?42(-+\7>-_"]Q]I8[@$^(G
M@-_#5K@D=3K=Q`I)Y_?>F*_IK(9Q\-,7QEPIX;YHL;PSGG"^.S_):GLJ=3%2
MQ5%SH.D\4TJM=0C"51.6RM;8_BOBC#X[Q6P/`O%OBK@ZF#XPR+C'*^%>(Z+J
MSIX=8*K*%;"5I817H82LX5I4Z[H<L*UE.47))KS+PAX`\(?L<_\`!6WP+X&T
MNUN+#P)9>)O#FB>'I-1N9]2>.U^(7@]=-LK^XN[N0&X,NM:E"DCAE51++@+Q
MM^S/^"]EO<3_``G_`&?KNW_X]%^(WB.T>4`JB3WWA1Y;1"%X\XVT5T5/3$1&
M#7B7_!;WX8:QX.^*7P3_`&@_#<4]G!J5C%X5U'7;96$>D>*_`=ZWB'PU/)M/
MS75QI.HWAMR/NIX3?<.1GVG]O3Q8W[5W_!+[X9?'>UAMCJ&C:Y\/_&'B6VL>
M(-%\0QVNH>`_&ELI<[OL,>I:S*\&224`W=`:^,P6-GF_$'T;_%>OB/KBQ$?[
M&QM:4FXQQT)5(J55O[6(J5)N#=F^6[6MS]#S#+UP_P`'?2W\%</A/JE?`5*O
M$6789)*=3`5*E":A37VI4(4Z<JJ2<>7GM)['1?\`!#+XI:+J7PC^*WPF6X@M
MO$WA3Q_+XU6R?_6W>@^*M-L;&&[B0R`RPP:QI=W')@?)'+$&^=@Q^(/^"YVA
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MRJ4E2G*%248MPDO>7O1OQO\`P6+U&7Q[H_[&GQMBS]A^)?P-N98Y(T;9;W+P
M^&_%*1ER2$+0>+$VHS%O]`DY^4FOW_\`V%_%T'C7]D']GW6(Y!((/AGX8\/7
M#;@SM>>%+*#PW.SD,1O,ND2%O4MP%'`_$;]H_2+?XN?\$</V=O'EM''=ZE\)
M=2\*Q3SQ@"2VT^UGUGX?ZE:.YY^S-%>V#$=-UM%S\HK[(_X(E?$[_A)_V8?%
M/P\O9]][\*?B)?V-K&[L\R>'_$\#ZW83S''!.I1Z^B]O]#'K7Y%XBY=]:\!*
M2IQ4L3X:<3YAE]2+WCAY5:L8N*3=HSO3:4K;H_??!_.'E?TG,:JD^?"^+O">
M3YGAY-W]JZ."H*HVW:\O:4J^U]))_P`UOAG]B/PU#XX_X*[_`!SU^_C267PA
MXS_:'URS$N"8KFQ\5S^&+&4!P261-1.,8P=N/ER#UG[>^H)_P]L_9HAU)@;*
MRO/@8(1+AH/)F\:ZFZ.V\$!_M[Q\C:#GD$\U[Y^SY^S7\8/@W_P5;^*/C0>"
M=6E^%'Q"T[XA^(X/'$5L9=`,/C"^TS79[!]1MV,<.J1^)[-(6MY!YNR02XV2
M+7RI_P`%G)+CX<?MB_`WXJV,!D>S\#>$=<LY`WRW&I?#_P`=:CJ+I\IZF.ZT
M\\<'R1ZG/UV29C@.)?&#(</E^90Q^%Q?`LL'1=-\RI57ETYNET_>PE!QDEU?
MJ?`9]D^:<(?1[XDQN<Y74R['8'Q(ECZ\9QM*O16:4_8U$NM-<T7>36BNKGCW
M_!23^U_V?_\`@I-%\5M-2XC:34/A3\5].:$%)=5CTV'3M.UNT1UP,R2>';BV
M.T@[;R0%LD%?TB_X+17]G\0OV+?A3XZ\-746J>&[[XJ>!_%UAJ$`9[>]\/\`
MB?P1XPM+&]B^4%893X@TXKD`XN%'45X-_P`%N_`-CXQ\'_`']ICPE/%>^'M1
MTR]\&7=^#\ESH_B^P'C?P/J\1P-EDD</B*.0YW%M1M",;2:]0^&T"_M7_P#!
M'36_#A\RY\0_##PMK&GV,"N#=KJ/P?U9M?T6WB&W"W<WAFWLH%P,!KM!C:`!
MSX?&X2?"?T<O$"O)2Q7">8_V'F-_BA1<O9P<NB=-QE-*3BN6:LV['1BLMQ=#
MC3Z6OA-@VY8;C;*Y\0Y;RJU.I6Y5B*DH=9*IS<MXQE[T6GH=O_P0U\76FI_L
MV?$/PKO"7_A7XM:K<S1!E$ZV'BC1-`OK.X.#D1-<V6J*I&T'RB.2":_/G_@H
M3X9\&>"?^"H?A76_'6AZ7JG@#QGJOP<\5>+-*OXG73=0TW49[7PEKEQ>CS5$
MNV;2=08C(7;`FX'YMW)_\$9OCA)\-OVF)OASJNI+%X=^..@PZ%+"Y9;9O%OA
MNWU#5O##QL0=DLD,NKVHZ`I>DMDA2OH7_!=32_LO[1WPOU%#_P`A7X.VMM(X
M^\\NG>+_`!,8W)'1PDSX(QRV>M?187(\7D7TIN*\L<Y4\O\`$+*\?4HU$Y+F
MCCJ,?:*+_FI3I2Y>5Z:.]SYG,N*<%Q)]"S@K-:5"G6S+PNSO+,-7IM)N#P.*
M<)-KM7PV)IM\UN9)WZ)_:W_!63Q)\8OV8/`7P(UO]FGQ3=_"3X:Z=J_B+PIX
MC\/^`XK#P_IR:Q?Z?::KX0GDL;:Q:,VH;2O$*R?)^\ENX@P)8AOF7]E+_@M/
MXS\.:EI_@_\`:FTJW\6>'Q^Y;XH>'K"/3_%.BO%)-"L_B?P_:-]G\06/[D>;
M+`EA=0AM_P!FG`./MSX_V=Y^U9_P20T_QE?2#6/%MG\)O"OCZ_N3L<S>)O`(
MA'C"Z,C#Y5>72]=9FQC@\8)%?G5^PG\#?AS^W;^R;\1O@?XB@TC3?BW\$-=&
MN?"WQRT,<>K:=X<\<1:EK6E:;J%P`7UGPC-XCT34X+A>1%Y22H%>%"/D^$,+
MP+BO"3-L)X@Y#'%U>#\\Q&7YAC\-"*S'"QQ%50AC'.T:E>E"J^64*M23<>9Q
MC*249?;\=9CXH83QWX?QOA1QG5RC#\<<-X?-,KRJLYU,MQWU>C[6>7NE4JRH
M4:M6FGRSI4HQBVGSQW7].?P_\?>#?B9X6TOQIX`\0Z9XK\+:W`EYI.MZ1>PW
MMA<I)@-Y4T8W1S*Q*M%(B.K*595->@1`B-0>H!Z*5[G'RGIQ7\:W['/[47Q/
M_P"">_Q_U7X6?$\7]O\`#M?%K^&OBGX-^;4(M"U&:X%H_C#P\J/B::%UMKIU
M@&[4[>*2.%#*'-?V)Z%J^FZ[H^EZUHU_:ZGI.L:=::II>IV%U#?Z=J.GW]O'
M=V=]87UN3'>64MO+%)%,A*21R*ZG:17X#XJ>&.-\-\TP;ACUG/#>?4_K&78Z
M";I5Z=HMQ4FE>I!2CS6]QJ491=I)+^L?`GQHRSQAX;Q-=8!9#Q/P]4>&S3+)
M2<IX.LI.-_?4:BIU)1FTG'W91<6[HVJ*A3/_`#TW?-]<\$X]AU_*IJ_*T[^3
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MXNX#A]9;Q%/A;C+@[$/,,HQ<=>3$?NU[\?MT[TJ>D>:<6KJ)^3_[.?\`P67^
M!'Q5?1?#?Q8T?4O@UXMO;BUL)-1NV&J>`)+V]ECAMG_X2*UE\[0TGE8[([^U
M1(BX$MUU8?L+;W<6K:=;W^F7<-_;75L;BUE@D2XM[M+@/)!-#<HQ5XV;8R,K
M%"J;E=@!C^5C_@K!^Q1\!_V;[KX=>-?A'=)X;3X@Z_K&C:I\)YKI]0MWM+73
M)+\>)_#<=QN:TT6.YFMK*]MCNMR^MV0MMH1PWVG^R]^U1XM^"G_!)6]^+5XZ
MZSKW@>]U_P`!_#Z;4V>6WE@NM?30O#(N_-D&^PLC?SO%`#R-/$"@!L5]YQUX
M6\%9OPSPKX@>%$,3AL-Q;F%+`_V?C'*C*%:=1<LH3E?]VJBY9OGE=7LTKH_(
M/#/QPX\R'B_CSPK\;*V$QV/X,R>MF=3-\MH3FZF$I4U*?UFIS>Q=;V<E*G)T
M:4^>T)*Z=O'-#_X)$_M0_'>+_A*?VI?VE[S3M?N1"VFZ9=VVN?%C5;<-*XC:
M]DO]>TRRTJ`"3/EVZS1JS2$[#DGY&\4Q?'[_`()._M)>%O"MO\2K_P`1>`))
M-.\73:?IMWJMMX/\9^!+_4+FP\00WOA#4+Z6VT/Q&DNG74;/%<-*LES;21SM
M%N#^R?LF?`']IS_@I0WC3XF?$_\`:I\?>&_`FC>)+K0;NUT74=5E;5-:>QL=
M3U&PTWPH-2@TW0]&BL=7LPC,DD[$F*16C137Q?\`\%!?V;_"7[*_Q<TSX8^'
M/B;XA^)\R>`[76]>O_$8L4O?#M[>:CJ0MM)!MKATLX#I$-K/LD95)U=GQRNW
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MC^)-V(8_-D^-6I!I"H+LL/@_P@D*,S<LJ(H"YSMY(`))/Y)PGFW^I'T=,YSW
M+<NP=;/<#GTL+@Z]?`TZL\%+]U"-2BYJVT6N65K:22U:/W/C/A]>(GTM,CX<
MS3,L5A.&LQX9IXS%4L)BJM.&,IJ%2=;#3]G5A>G5E)*I4C%RO=)I),_%CXA>
M%/V@/^"7'[25EINA^,56YM[32_%MG<>''U"V\,?$CPO/?26\UAJ^@3R+YOFS
MZ?J5M<Q3&217M8VAG3JW],?[6_[8%G\&/V0G_:`\*0Q3ZGXS\/>$)OAG%?1H
MT)U+Q[;V%UI5W>6S2JLL5I973SR(C`A8N,C-?BK_`,%S$9_VDOA4X*`K\%].
MFR`%):+QIXFD##;T;=$O_?..F<_0'_!1?2;V^_X)8_L?WEDLLEKH=C^SQ>ZH
MH.56VNOA'>V*/S]Y1=WUJW/&Z,$CU^HXARW*/$+_`(EQS[B+!8>GFW%F+=#,
M?JM*,(XBG"M"TJE*FK+GG"SC:W*Y)6O8^6X5SC._">M]+_A'A3&5:F4\!8*%
M;*Z%6M.L\![6#IQK4IU6ZC=.,I/WG\4(-]U\!?LU_LA_M&?\%)O$GB/XL>*O
MBK=Z=:>&]2CTK4OB7XRGU?Q)KDNM2VRWZZ!X4TJTO[8V=C:K+IL\R07-K9M%
MJ<:!%D1WKDOVR;']K;]F/7O"?P%^)_QB\7>(-%\(6NO:W\.?%VA^)_$VG3:[
MX<\52:7:W5M=WPU47*"RN?#4`2RNI+@VIU&06]S-`P"?LY_P0_\`'?A?5/V9
M_$_@&RFLXO%/@[XBZY?ZWIL;EM0DTSQ(EC>:1J<L`'[N"20WL"^BZ<J_=``^
M&_\`@N=XU\,:W\:?A#X4T.]LKK7/!W@+Q$?$\-FZ326"^)=9TN?1K/52@S;W
M+6VF7DD$;DXCDD*;5)S]5P[QCG&<?2%QWAWF7#N75.%,AE6IX7!K`4J;PBI4
MG.C7C4C'GBJWNQC?2TK:7U^'XI\/.'\D^BMD/BIEO%683XXX@]E/$XC^TL3!
MXV6+QB6(P\DJTDI4'*^D9-\LK[G[<_L>W/B#7/V&O@[<Q7VH7GB?4/@W;/:Z
MK<7LD^J3:U<Z5=0V=V]]=[V-YY[(5FD,A#J"5(7G\B]%_P"".O[17QUT^U\7
M_M/?M++IOBUK>.YTW1)8-:^+-_I33Q+++_Q-=<US2HM%Q(2/LUE;2J.IN"Q-
M?83_`+0VN?LP?\$H/@]\3O"5M:77BY_AQX'\+^%AJ$27%C9Z]K]U);6NJW-M
M*P6Z2VMUNIA#D&4PA,U^=G[)G[*W[27_``41\.>(OBS\7/VJOB-H_@V'Q#>:
M':6MCK.KZI=ZWK%H()M5>#0UU.+2-`THB='C\J-[B(/Y;*,!C^/\(X3B;ARA
MXB\:X?B/!\"<.4\ZGA:F85<O_M&O'$TJU6+PV$H2BU&"53W];Z*R25S]YX^S
M#A/BFKX/>']7@[-/%#B^/#U/&TLLHYH\OP4<'7P]%K'8RI?WZMJ4XTYN-[N5
MW>23\>\.^(/C_P#\$O\`]KCPG\*;SX@S:U\.[K7/#EQ<^'K*[O8?`?B/P9XJ
MU)[*YU6T\-37(M_#WB2U0.[&!5D,EN"3)"61OV`_X+2>)=?\.?LJ>%M8\+>(
M==\.:@WQ?\*12ZAH&L:AHUV]F^C^)9)[>6YTRXB:1&2-V,;$Q,T2;T8+@_@1
M^V1\!_#7[-/[2FG?"SPW\2_$/Q232AX(O/$.I^)19F^TK6-:OYKY]$D-E*XQ
M'I3VCA3C;YN!7[M_\%NHXQ^R+X2C7<4D^,_@T.I(QEM!\4#80`,<%_\`OIA7
MZ-Q/E^2YCXB_1PX@=:AG=3B?VGUW$?4H9:L737L90J5\,ZDWSR]O;FDU>"2V
MB?DW!6:9UDWA-]+'A6E7KY/@N"G0CAL//,O[2JY94G.I"K1ABHPBG3A*BTN3
MF]Z]F?F!^RY^SG^UA^W]\'[OPQ<?&VZ\)_!'X;WVJ:!9QZ]<>(M?;QAXQNA/
MXB>/5;*+4%FU>VC;6[6![F[NG6"(1PVEG<M#(B?,O@/XH_M-_L+_`!K\<_!;
MX?\`BF<^(++7=9^',GABVN;W6/"VHZ[JL"Z9X?\`$&C:/>/''!J<4]_IUU:2
M^1$WFRA;JW8;H!_0/_P1<MX_^&+=+81K&\WQ*\?2SSQD!I)TU00!V)'S'R88
MU!_NH!7XP?&:&WE_X*\26LT:O'+^U7\-%>%P60J=<\$!T.>H`P,=,`5[O#?%
M,LX\0_&KA'-LFR^KPIP[ALQJT,#'`T)PG/"U;N52K&/M)2J2<IN=W9I.RO<^
M8XNX(_U<\)OH\<>Y5Q!G%+C?C3'9=AL5CEC<4O9T\724HJE#6GR15DK:O7?8
MZ+]KW_@GC^T9\(_A;_PU/\5/C5:?$7QG:7NBMXYMI+S7W\1^&)=7N%L]*DT'
MQ;=WK?VB([EX4F^S)81PO_QYM=@"0?K[_P`$B/VA/&_QK_9U\36?Q$\0WOB;
M7_A9XQG\*Q>(=6N&N]5U3PQ-I%EJ>C_VIJ+OOO-0A$T\1N'P[1Q)YF^0-(WJ
M'_!5U?\`C!?XPN4(\N7P?@[]PBQXRT([5'9<\8.1A1D&O@/_`((J:?=ZK^S9
M^U3I6E8&HZGXI?3+"1B4"7=_X#GMX-S(P*+]JFC)(Y`&01Q7Y9F6=5?$7Z/&
M;<0<5T<'#.\@S_"X+"XG"8&GAYT,'6GATZ*A0CR2HPC7U<VI+E4GK9G[AE/#
MN$\(/I29)PYP=7QZR;/^&<9CL30QN*Q.+C6QM&GB)1KN6(U5:4L/LER^]TO9
M?)W[1G[6O[1/[>O[1]S\`/V=O$&J:/\`#K4]>U7PAX5TKPSJ5]X>T[Q9I6CR
M7=MJ7C7QOK>FAY;WP]+`ES/%;R%87M9+93"9C))+=^*?_!*7]HG]E7P#?_'3
MX6?&'3M8UGP1IU[XD\66GP^MO$G@'Q)HVD6$<;:E?:%?V]X$\5"*'[1-,DAT
M^0QJ?)CG()/B_P#P2<UC2O`7[;GA#1O%\<>B:Q>Z1XN\%1VVKK'!/!XABL'6
M/37*J,7$KV5X%VD#?;L`,<#^J[]HWQ9X>\"?`CXO>+?$-Q;6.B:+X`\4M=&Z
ME>V^TS2:+J>G6=@)>"D\UU=V,,17!#W/!!YKZ/Q&XSS+PAXLX#X!X!R3`4^%
M,1AL%+V5;"0K?VU'$SC"M4K2JQ4I-J]E"THR2W3M'Y'PEX$R;QUX*\2?$SQ*
MS?-JO&F#QF/4:T<UQ>%64/"TJE7#PI8>-J45%QBFI-Q<7;=W/S<_X),_MX>)
M/VC]+UOX/_%G51JOQ/\``^DVFOZ/KMQ%''>^,O!;R6]D]]>-&1'<ZQI]_=6D
M=W.L<;S1ZO9LP9TF>3]K:_D._P""(NCZO?\`[7T^J6L+R6'A_P"$_B1M7N%*
MK';VM_J.CV.G6[KCES>RRJ0./]$4D912/Z\:_$/I#<,Y)PKXHYUE^00A0P.(
MA0Q#HTX1A"A5K4U*I1@HN2Y8RNXV=K.R221_3/T2>,N(^-O!K)\RXIQ53'YI
M@J^(PBQ%6[G7HT)J-*I*3^-N#2<^K3OJ%%%%?B!_3(4444`?R6?\%O[3Q%#^
MU/X3N]0C=]"U'X1:,?#DUP9$M'_LW7_$2:K9[E`9Q%>3K)/C)$>L*PR,D?NW
M^PI^U]X(_:G^$'A[5K;7].'Q,T3P]IEA\2/"KB/3]3L_$5G:16VI:]:Z8TI:
M70KV\VS6[P[XX1>I"[+(=E='^V+^Q_\`#W]L7X<GPIXN5M(\1:'/)?\`@/QG
M90Q3:KX:U:9##=^06.V[TN[@$<%W;2?)MC5U_>JI'\I_QC_98_:O_8/\:6?C
MR:/6=&M=*NW@T'XP?#:\U"31&=I6MDLK_5;.**70KJ5C&ILM1CA64@QE73)K
M^P.%J7`WC9X7\-<`X_.</PCXA\'-T\%+$54Z6.IS:E+D2CR*%5QC[1)^UC.*
MG'2\)?YY<9XGQ&^CCXQ\:>)V!X=K\:>&7B+*C7S!8:-7ZQ@:M*]*#J)PYE4H
MN4Y4[VH2IR2DXOWU^\G_``48^`GQ&\6_M+?L0?&_X:^"]7\3CP/\2]$T'XBR
MZ'8/>WFEZ"GC;PGXAT;5-16)MUKI$-JOC7S9BOEQ&Z_>.F]=WP+_`,%P-$U+
MPG^T3\#?B?I$YTS4M2^'RQ6.HP@?:8M>^'GBRXU2UOD8'GRH_$M@Y]HAC)R*
M^GO^"?'_``5;O_BAXDT'X&_M%6NGVGCG59(]+\%?$?3H;;3+#Q3J;H570?%&
MFH$CT7Q+-<(_V>:%3:W3ADG$+[)+C-_X+T^'[&Y^&/[/OB_RE-YI?CKQ)X6A
M90G[S2_%/A@ZE?,H&!L,GA:Q"<##2@849QT>'U/C?@?Q@\-N`>,\FC1QF08+
M-\MH58MR^N87,88FNJM*=W3G3IRFX46HWY>7VD5*+YL/%2MX?\?^`GBUXG^'
M>;U<:N(<;E&9XG#M1A6P>.P'U?"J-6'+STL0X>_-*4X-W<*DE))?2O[7FFP_
MMI?\$T'^)6CVD4FOS^`_#/QQTNQL7%T]AKGARQ?4?$MG8W"$DW<6GGQ#;Q,"
M=YM8USC-?GU_P2G\26'QH_9]_:I_8K\37%NTFN>$]8\8^![*]C98$L_$"2:7
MK4MI;@9AT_3_`!@OA>\C3'+:Y(PSAL>)_L\_\%;-2^!W[/WAW]G_`%CX#6?Q
M#TG3-%U[P[)K]]\3)]$EU+3M3NKY[N$Z%-X#OEG\M=3O(O+%P`Y@5,J#D><_
M\$A_%LWAG]M?P'ID2FSC\3^'_'?ABZMQL=8VF\/B_MX)2D4:;X[S0K10NQ?F
MAD+QHVW/U.%\/>*.'?#+QCR'&X+^SLKX:S&&<Y/4E6I5'&6$K5)P@HTYN<)/
MV2O=4W[S=M=/@JOBIPAQAXQ>!/$>68V6.SOBC*5P[Q/"="I24'C</"C3JU)S
MC&-92^L57/E<E>E!JVJ?B'[+GP,C^-?CKXE?LR^)8K7P[\3-4T3Q1+\.]8OU
M6WO-$^+?PWFO8;SPOJ=VA8IX<U6R_P"$AM;L1%VC>"WO(`[0)G@O&/Q3^(F@
M?"#Q%^RA\2-+OTC\`?%&'Q/X:L]3=$U7X>>(]/MO$>C^)O#H@C=DGT.ZCU22
MZ\M'>*&ZM(;BW>2.3>/LOX_,WP%_X*TRZ_I#IIL,7QW\"^*UDC)1&TSQW)H,
M^O!DP%19EU6^13WCNYBQR%W>\?\`!;C]G6U\&_$CP3^T!X;TG[-I/Q)2[\*>
M-C;A%@'B[1;3S]%N[AU0$RZAH*:A$S<L6TP;N.:_6,OXPP^9\>^'^#XAA"ME
M_B'E%#.,NJ3NY87-L%A%]8C1EM&&(4X\L97?-=)WJ3YOP[,^`,5EWAKXDX_(
M%/#9[X29SB\BS-0M_M>28^HU%XB%FI^RJT)VEIR4W#=PC)>@?L*Q1_%K_@E'
M^UC\,YXEDG\&?\+*GLH9")2LEOX9T[XE:3LD8X!'B!9F!SD;CS7CW_!#;X@W
MVA?M'?$KP`))/[)\?_#,:K-:(.)]?\$ZM:MHLA<C"B/2=9\3IR0";U1UQ7KO
M_!%EH]8^!O[:WA&X=I+232O#T\T3<H&\0^#?&FCW?'/+1:+#GCD*O7H/B;_@
MCW>S1?MO>`/)(`OO"GCR&<.=B&(>%=0N%W2YQ"!.L+%BKX\L[5+%:_/<[RW#
MU,N^EAD,J:EAJ%3#YA2C)I*%=8.%=M.UDI3C=Z7;T33/UGA;-L1A\W^A%Q%&
MHUF&*I8S*JE77F>$CCZF'ITW9-N,(5VDG>RBME<_LHA:)6)VA65O+#!&W%`.
MA^7I@<'H>,5_/S_P7K\"I>>!/@+\4H5B$NA>+?%/@6=MIW21^+=(LO$&GLY[
M+%<>"K_'H;X]S7G/Q5_X*V_M@_#SXW>(O@[/\!?A;I>OZ5XKM_#6G>#M1N/%
M'B'5]7NM4EAA\/6EOK]CJUO;22W4%Q8,76VE"->H=S+]WWC_`(+`ZSXIUC]A
M;X4:A\0O#FG^$O&NM?%+P6^K>&K+53K=KH>L3>&O%%UJ.FVNJF",W7E6J7L>
MXH-CYCRP4N?PSPLX$XL\._$WPASO-XT*>#XEQ"EA(PQ,*TJ^'J8:3DIP@^;D
M2FH\VD=4GK8_I7QD\4.!_%GP8\<LFR&.+HXK@FC#ZY+$X&M0IT\13Q5'E]E6
MG&,)U+PE)P7ON+4DK790\:Z9#\</^"*'A[5`5GU+P#\,]"UJT?!D^S-\+?$,
M>F/&63C,.@Z<Z-C(PI*YKFO^"$^NP:Q\+/VB_AK?HL]AI_BOPGK\UDZD+]C\
M<>&]6T>X!''R2'PC<KZC9D@`H6_+_P``?\%$_BI\+_V6]9_9:L?AEX.U_P`$
MWOACQQX=O/$>H?\`"31ZR;3Q4FK+J,D48E>":6$W]ZYP&6/[+E\')'W7_P`$
M$Y-07QM^TO&SJVGVWA?X=1WLO!C:^M]:\66UB&D')46UO?,A.-RW)(YW8_7>
M,>!,ZX7\(O&["YBZ5#!X?B.ECLJY*D9SC&KC5!Q?*_<M&#M%*,KN[NM'^&\`
M>(?#G&?CO]'C'Y-.M4Q_^K$\ISF56G*G&M4_L^I*D_>5ZD&XSE4FW*-M%9W9
M^)_B--:^`OQI\00>';LV^N_!KXGZO::)J`4%XM3\`>++J"TO,#[JF[TZ-\X_
MY:?4C],/^"NGQ3T7XQZQ^RC\0=%55B\4_`63Q'+8":.6ZTZ^UGQ%-YNG3*C?
MO)(KZPU*!G0&,M8L0VUD+?F3\:O$5GXQ^-7Q>\763BXT_P`5_$[XC:[9RI@I
M-IVM^+]7OK)B5)'S64\!(4GES@D<GE_$WC;Q1XIM?".E:_J]QJ%AX'T$^&?"
MUO/M*:5H)U.]UC[#"?+#%/[0U+4'RS$CS\`XZ?TS4X0J9QFGA;QI)1CCN%Z$
MX5V[>TJ+&8:'/36CYHTJEG33^%.5[MG\71X[AD?#WB[X?TI2EE?%&-A5PZC?
MV:JX/'>TG-=/?HTXTVUO"WVM3^KG_@EC-#\6?^">,O@&_?SH[>Y^+7PYN3(N
MY8]-UU[J]MXL8Y466LQ-QG[N,YR*_(7_`((X>.]0\"_MD6'A6]N);!?'/@KQ
M?X,U.SD<O"-0TS[)XAC00XP)4U+1YERI)/D8R5(-?J;_`,$,;J:7]E7X@VY8
M[+7XS>)4B5L$I&/"7@>8KTX_X^Y,_6OQ;_97G.B?\%._!D6DD/;P?M)_$+2X
M%C.(FL#KWC;3D\H*>8?L$BG!'13P>*_F3*LMP]?-_I9\.\G^R5HK%)/I5;Q&
M(33:LK591MI>T5KH?V1G>>5<#PY]!OC9W^O86I'+Y)-^]0<L/@^_-)NFG=-\
MOO2]VS/T'_X+A_L[V^FZK\/_`-I3PYI\%M!KLJ?#?XA",F&:]U6&(WOA#6AM
MZS_V98ZM82.1C-O8\A`S#[,_X(R_':^^)_[,!^'VJ3B?6?@IK2>"X7$>UG\+
MW-E'JGA:0.0-UO':O>6D)ZB/2U#*"*ZW_@L=!:G]B'Q9+.(O,LO%WP^FTYIV
MS,ES_;L$+O$3R7_L][L'V)[9K\Y?^""^JZC!\4?VAO#]L[2Z/=^!/!VIWG4P
M1:CH'BK5=.TN2,]!--8>(-9W<`LMM%UVD#XR,9\7_1.Q\\TJ.KB^!\QA0P%2
M6]*A[2C%4X-WTBL742](Q=U3BE^E8I1X"^G1@*&2+V&#\1LK6(Q].'NQG5E1
MQ-1RE"-H\SE@J,G*2;;<Y7YJC9_3HG4!>A(8CI@$#C\SC\:L55CXF(`X*G/'
MILP:M5_(2=W+NG9OO9;G^@D8J,4HJRU_-E*\61TD5%<GR7*;`,E]K+M!R,/\
MX*\CE>H[_P`W7Q9_X)__`/!1/0OC?\8?B1\#/B+9:/H_Q%^(GBCQE96?A3XF
MZWX7\RPU35;F72;36]!GM[:S_M*/26M8I9PUXQ=&*OL(5?Z1[@-O!`!`7))7
MW.26)P``,\U3FF*X`$C`X/RR1H"".,;<Y&,=Z^UX*XZS?@''8S'Y9A\'BUCZ
M7LITL=A*>,HN-U+G5.>BFK+6_3;5GYAXG>%G#WBI@<LP.?8_,,O635_K%&IE
MN)KX>O&IR\OO2HQNU;7E;M>SWL?RWZ/_`,$A?VT/C=X\L-?_`&BOB3IFFVSM
M!:ZSXGUCQ=J'Q!\71:1$Y$EEX=B$:00SF$L(BXM[=&;>8B5"G]RM=_8K^%NJ
M_LJS_LD65KJ6F^!$\)1Z%IVL12P/K6EZO:S#4+/Q7YP58[K6QK<4%Y+A8TD=
M"A`W9'V4K)@D(H..-GSMGCIM!/7KQ[TD4D@9]V0-A.27(7MR&Q^@)KV.+/&?
MCGC"MD\\9F%'#X;AZ<:V%HX*-.A2H5(6<:D:44[RC;9NR6B2NSYW@7Z/?AGP
M-1S]87+\1G6.XKH3P^88G-<14Q.*Q5*HFIQE*H[KF<I.T%%7?9)'\Q7@G_@G
M/_P4S_9UUG7M"^`7Q6T#2O"NN7@:XU;0?&`T31]0,>(;?4[WPKJ=E<M9WR6L
M<2OY)>8")4CF,:HJ3_&#_@C#^T?XGM?"WB73?B7X>^(?Q-\11ZUK'Q?\2>+M
M;UF.VNM?FEAM]%L_#\DUI)<3P1Z6;F.:YG(<;MD:^6J@?TT"Y*.@;))(&9BL
M;98Y41QR,IZG`XP2<5JPN)(D=2K*PRK*596&3A@RD@@C'3UKZI?2-\0UC:.:
MX..78',*RC*MC,/EU&C7QBBE&*Q59IUJFFK2<(NR=M$?$2^B%X3XO+*N39C6
MS?,<K@H_5,)B<WKUZ66N-[O"TK^SHRFFTU*,K1;22>I^;/[8O[+/Q4^/W[%_
MA[X&^%Y/#T/Q"M(/AF-4GU:[DM]$2\\-V5G#XCGMKF&W>297ECN3!E`2)>0.
ME-_X)E?LK?%+]DSX+>+?`?Q3DT&XU[7?B3J?BVUD\.7UQ?V9TZXT#PUID8N)
M;J"-UN3-I<N``5`CSGD5^EM%?GM7C[B.KP?C>!WB8+(<?C5F%2/)[[Q":=U-
MO1-*S5KVUO?4_6Z?A)PC2X_R_P`28T*JXERS+?[*I24TJ2PJA[./[M1LIJ.E
MXM)O5Q;U/PS_`."F7_!/GX[_`+6/Q>\$>./A==^"(-)\._#>V\*WD7BG5[[3
M[Q=2@U[Q!JK-!#:6D@FL)%U2P#Y()-FPQ@#/Z$']FGP_XQ_9(\'_`+-WQ<BM
M+K3=.^$'@?P/X@N].N#$=,UGPMX9TO3UU_0[]@#!/:ZQIJW%M(0NWR4)"GI]
M9W3%IE@!4@INVNC,IYZY4\=NU>8_&'PWX@\8?"GXA>$?"UQ:V>O^*/!7BKP_
MHU[?3S6=A8ZMK&BWNGZ;=7,L$3RP0Q7L\4C,D;N%0E58X!VQWB+Q)G&7<&<.
MXK-*6#P/!<V\!4I-4J]'FJ>TYI3A:4K3?,FW?HKG'2\*^#LESSQ'XVP^5U,[
MS/Q`H1I9GAJSEBZ6)5)-1H0PTX.$(2B^5Q5[[WN?SEK_`,$=OVN/AAXZN=<^
M"7QN\+66E^7/I^E^-8?%'B3P%XL_L"Y<-]BUZ'PY8*L>]]IEBMKPVY?:47<H
MQ\1?M]_LUV7[,GB;X=>"M4^(MW\5OC%XJ\-:QXW^,/B6ZN+V:$ZE>ZC8V?AZ
MTA.I7$D\2(Z:U*);MS/<+>F5B@1E'W/;?L\_\%G?A'8CPQX,\>>)=?T94\BR
MN[/XJ>&/$D:(T9"FTNO&5K]LCC7[P+/(V%VX`.X:'P1_X)%?M#?%OXJ6WQ,_
M:_\`$UBNCS:FNJ>)K"3Q%_PEWC'Q?]D,#6&C7MU!$;:STMRUX)V$Z/;)B"VB
MD25WC_M+A[Q(Q/#^+PW%7&GB[P]Q'E658:M&C1RVC1CFN+K2I>SHT\945)5Z
MJH7YH1NU=<TGI<_SLXD\*L'Q9EKX-\//`KB;A;/,UQM"5>MF^(KPR_*J-.O&
MK5KX6C.;H/VK7+/D5UI9+9_I9\/_`-F72/VD_P#@FC\&_@KXNN+[19-;^$'@
M?5])UBWCE@O]"UM+&+7?#NJFTE*.P5+Q?,MY-A>.X,<BJ=P'YB_#O_@GI_P5
M`^`=QK'A#X+?%+0O#7A#6-3N)KO4-"\;-IFD3M,[*FK2Z!J-E<2VVHFW6'S)
M+<12JRE$D:-5-?TX:=8V^F6%OIUE!#:6EA#%;6=K;HL=O!:V\:06\$,:*`D:
MPQQ@*!A<8'`%/ENXX-WF.J9`(#*<G*ECL*@[C\IX'.2!CD5_)61^,O%61RSZ
MCEE#"9EE'$&/KXYX/,,+#&X:GB*DG-UE1F^7FO;5WUMTN?W5Q)]'S@?B>GPI
MB,YQF-R3/N%<MPN70S#+<;4R^O/#T(1IPHSK4[.48R<K1?N/G=XMJ+C_`#%_
M%K_@C!^T9JE[X7USPC\0_#GC;QOJNERZW\4/%_C'6M9MGO/B+=7U_=RW>B^=
M#/<W-E'%+IB>=<R^9<-IZO*H(X_5W_@H[^RK\4OVK_@'HWPY^&\^@6?B.T\=
M>'_$UV?$%Y-IUE_9NEZ/K]E-;"ZM8I&:[$^KC9A<'<6SBOT=M[CS%0F-U+2;
M0#V.W);)^\N2`",C/0XJ]6&-\8^.<WQ7".99AC,-B,;P8ZCP=6.#HT;^T<+J
M=.DHP<8>SC&G%17+&-DV=F5?1V\-<GRSCK),!AL72P''\:$,RIK'5I\ZHJ<H
M6J.3G*4O:RE.<Y3<F[MZ'P+_`,$\/V</B#^R[^SGI_PJ^(DFB2^(;;Q?XOUZ
M1M`NY]0TM;36M46[LA%-=01OY_E`%P5^^I.>17YU?$'_`()G?M$>)/V^)OVD
M]-N_`J^`#\:O!?CX0S:S?0ZZ^A:#=:%-J*M8K9F(7^VPN3!E_8X)`K^@^DP/
M0?E7/EOBMQ?E'$/%7%&`Q-*CFW&-+%4<9+V2Y7'%N]5TX<UHOI&_,DMTSTLV
M\"N!L[X3X(X,S*.+Q.2\`5<)5P">)G[3FP<5&DJLU\:<4E*RBWT:/C7]N?X&
M>-?VB?V:/B!\)?`,NFVWB;Q/_81L)=9E>UT\-I^NV&H7+W%Q`C-$_D6TC*0I
M.X@=Z^=O^"7W['7Q7_9!\!_%'P[\4IO#<]_XO\9Z;KFDKX9OKG4;865GH<&G
MW,E[+=P1/]HDN%)"X(PAZ<9_52BO)PO'6?X/@S-.`J%:$>'LXQ%/$UX<K]I*
MK3=)Q:J*2Y5>C!NROOKJ?08[POX6S#Q$RCQ/Q-*M/BC(\)4P>'DZTG1C2JQK
M1DW3=U*5JTTKOE6GNW1^#'[:_P#P2.UCXH?$;5?CA^SAXBTKPCXWUK4H=?UW
MPKK%Y?Z#8W'B-&EE;Q1X6\3:9!<RZ%K+7:P2S0F"-'8M+%=P2O(!\L^(?^">
MO_!4SXV65AX&^+_Q/L-3\'6EQ;,5\7_$R[U;0MUIM-K?7.GZ;I=U<7]U`5!A
M>6&5\_,[%^:_J,P#U`/X4M?=Y-](#Q!RC+<MRZ=3`YR\EI^RP6(Q^"HXK$X2
MG:RA0K37-%1LFF^9W2U>Q^6\1?1/\*.(<[S/.'#,\FIY[4=7,<%@<RQ&'P./
MFVG)XBA&33YM;J#@M7Y6^'_V)OV*/!7[&7@*\\.>'[R;Q'XK\3W=IJ7CGQG<
MVT=G=:[J-K"8H(H+6-B-/T:!'=8+=2P4'.>M?<%%%?DV=9UFG$.9XS.,YQDL
M?F6/FYU:L[<TI/1:*R222C%))))):(_>>&>&<DX.R++N&N&\!#*\CRFG[+#X
M>%^6G"[=N:3<I-MMN4Y2DV]6%%%%>6>\%%%%`'\\?_!9;]J/XW_!WQ7\,?AA
M\+_%VK_#[PYXG\)7?BC6_$'A_P`NQU?6;^+6_P"R8M(&MB,RP6UM`%F>&`Q[
MFNHVF,B@+7*?\$BOVF_BK^T+XF^)?[./QQU2X^+_`(&G^']WXI6Y\;'_`(2"
M^LX(-7T/0+GP[JL]^K->Z5=1:P\VVZ:9T>W40M''E3^C/_!1_P#8S/[7_P`'
M88_#4%E'\4_A]+=ZY\/[J[F-M#JAU"W@.N>$;B[4?Z%;7\=A8F*<AECN(8&;
M$8DW?&__``2<^.'P0\':?JW[.?B;P%IWP6_:5TN^DT?Q1'JUC'I.I_$632"J
M6[?:[WYXO$D<AD272U<K*D27MJ'A8E/ZQR7-^$<7]'+&99E7"\,RXSR2JUB)
MX>E%8O!PC.,XYO.JH^U>'C&*IV@[1FU>T4VOX%SWAWC3+OI99;F'$G'&(RGP
M^XG<)X*GB,14E@L>IX6G1>1QH2DZ/MI3ESOGC>4(RLVVK_DK_P`%&_V<+#]C
M_P#:8CL/ALYT?PUKFFZ)\3OA_"9)"?#%S_:%Q#<:7:2S[B;*T\0Z--);(2WD
MVXBBW':Y?[[_`."W?Q/7Q)X'_9-T"WB:V7Q#H.O_`!3U*S?=]JT\76D>&8=$
MBGC$G&4U/7XV4KDO;*%90KJW"_\`!1JXTW]LC_@H-\(O@)\/;B/6V\.VNC_#
MWQ5>V#J\%A>W/B.Y\0^,T-^21.VG>'I]05U4XCG\R'[RX'-_MB6DO[57_!4G
MP1\#K&)+GPSX1U;P-\,[F"+$%M;>'_#XN/$OCM_EX+"WNM6B3`^]9VP_AK]<
MX>Q%?-,3X)9_Q;6FLVX+X;S3-,=5FW[2."H4_J^&J2;?-SXEJ4Y-ZN2DS\#X
MJP6'R3"?2'X8X)IP7#_'O%>3\/Y71HI*BLP=5XC&TZ<8^ZHTFX17+[J222W/
MW9_86^&-G\._V1O@)I5[I-KI>J2_#K1=?UB*6QMX;G[3KT4^OR07[-"'-U&=
M7ABEWDG-N1@$'/\`.I_P3QNA\6O^"F-MXWL#(MIKGC+XT_$9;F,;?)TO6O\`
MA(=4L`P96$:B'7[*-`1A6@5>1D-_43^T_P"-;?X5_LY?&?QHD@L9/"OPT\5W
MFFR1@HL6H_V5=6VC0P[!A)'U2>R1,=&D6OY[?^"%GPOEU7XV?%_XENF-,\!?
M#C2/"-J3@YU_QOJK7:>6?X1;Z)X2O?,Z9?5_3`K\9\.LZQ%7@#Z0/'^/FUBL
MXC0PJYI2DJ=7,*E><HI2;5W&M"-K=%;4_H/Q<X:PL/%+Z*_A5EF'IJCP^ZN8
M5)PIPA.M'*J-"%ZK@E)\_LJEVVTVW?N?/O\`P4F/_"1_\%+-:T_3$`O)?$/P
M;T)%CSD:@=-\-6J*`"<2+)>P?1D'&.*_9/\`X+4Z?:W7[&;WERJR3Z9\3_`U
MU9EL;EFF?4[!F'&=WV6:5,@])3G/%?CS>6+_`![_`."OTEHL;7-NW[32/<*C
M?(^F?#"[@FOMW/"F/PA`JX(X=S7ZE_\`!<WQC;Z-^S)\//"`GB_M'QK\4M,:
M*'/[RXTOPMX>UG5-2NT`X`CU"XT4#WN<U^A9OAI4N/?HK<,4'?'9;@,'B*JO
M]BM3IU&N]DJ3OY;K1GYAP_BZ>*\+_II\8U4G@\ZS/&X>G+3WI4ZM:,9=FW3Q
MM))K;E5N[^;_`/@C#:S:#\`OVTO'%Q&J6+:?I%F)FSY+R>%?!WC35KLDYS\J
M:Y:[^1\KC'/)^6?^")_A5];_`&PI-1A):/PA\+?&.L2LZ,8UCO'T'P[8SEP,
M?/<:M-A",L$R/NG/VO\`LS6+?L^_\$?/C+X]NHDM-0^*FE_$C4;=WE"S1OXJ
M>#X::%'&0?GF2"TFEXZ>3[DU<_X(5_#J#0/AQ\;?C=J=O';KXAUK1_!&FW[B
M,);:1X,TVXUS6+BVD;F*UDO=:M$F'1AH41P2G+XKX@H?V!])WB"FW*CG>:8'
M(L/+K4K4J2P>(:[\RC.H[:W>G87`_"M1<4_0UX8Q,4ZO#V38[B#%II-4Z.(J
MK&45).Z6LH15]M[Z7/C/]INX@\9?\%?M!L-*MM\EA\<?@+I'EQERS_V$_A:^
MU`LP8NK(+'YMK*=PD#Y!`7[%_P""]/C4V?@7]GKX7QNI.M^)_%GC^[;C"IX7
MTRP\.VQE",N'DN/&]VX(')M7/8@_#O[$5U#^TI_P5#'Q2$4KZ3??$'XB?%R(
MSY,MMHEK%K$GA4."3ME2WU70_97@&.F*]?\`^"O=TOQ<_;D^$'P8LI9/M=KX
M8\`>"98D8X@U/XF>,+UIID[>8MM/I*Y'50,_=KVX9;3P_B]X+9#BX)2\/N%8
MXO$K2T53PDZM2]GNHI._=*W4^9AFU;&>!GCYQ'@H*>)\3^-J.7X*FDE&K3KU
M\/"#4;6:<5)VMW[GV9XNAL/@/_P1BTZWNHHK/4O%WPBT&RC41)YW]H?%G5O[
M2NF1'4>7J`TC7+SDJ51X5)0A2#\Y_P#!*:*7X3_L:?MH_M`SM]BW65_INF3R
M-(JRR_#_`,!ZIJ%O/`68%U_M?QFL$9#Y,MM@G<"3ZE_P7&^(VG>$?@]\#/@7
MH5O%:1>(?$5WXGN+*#$4%GX;^'VCP:'IU@EO'@)#)J7B6V\I>@&B/@``5SWB
M>Q/P._X(B:3IT<7V+4/BA8>'+V^9ODE<?$'QC%KTCEE/S#_A'[=.3U4[>E?"
M9;]:S3POR[V_.\9XS\:K$24Y2;^KQQ$>;=RM&-2$TMM->MS]$SF&"R;QFS5X
M2$%@/H_>',J<:E.$8.IC9X"<%-\J2=1K$25W?=Z)H_$?X`?`N;XO^'OCAXBN
M(=0M]"^"_P`'M7^)5Y/;,D<1U&UO=-L=*TRYFE@<%9TN+^38I21DTYBL@P<X
MWPT^#6J>/OAY\;?B7*)[3P_\&/"GA[5;^\C$8AFU[Q/XBL=$T+097GSY\LUF
MNO7>$V,D>E*K-F0;OUP_9$\!IX,_X)3?MJ_$ZYMFCU#XF1:QX>MY%.9Y=!\)
M1V?AJS7`_@76M2\3!1Q]RJ&L_">#X#?\$<M9UG4H3!XH_:!\<>"/&FHF:)$F
M72+_`%U+KPQI;D#+NOA[28[EP3C&IMM`!(K^@,7XK>SSS.,IRVLY^RXJR;(L
MN6Z=*CAJ,LVDU;2W,U=WULTUT_F;!>"F%?#/#.?YG35*E2X-S7B?,?*6*Q&)
MPN6PNW?WI2P;WOHWKK?[B_X(L2V_A/\`8M^('BC4I/)L%^)WC_6[FX<84Z?H
MGAGPM9WURA.,HO\`9;9//(/;`'X[_P#!+[0=0^)_[=_@'Q-<0$RZ-JGC3XBZ
ML45C&LSZ=KK.RJY=E@-]JUF%RQ;,Q!D)(-?JE\"=<A^`W_!&'Q/XOGEBM+WQ
M/X5^)<6F&8?*VI_$+Q3?>$]+8A>6BC6>*:0#DQ61YXKY4_X)+'P+^SS\-?V@
MOVTOBI,VGZ!HMK8?"WPG&6#7NIWS-%K^O:/I%N?^/G7+W5)?!5C9(""SV=PG
M(<D?CE''RPV$^DSQ%AZ,L1BN)LW629?""YIUZSE*@H1BM6^7$*22W<5V9^[X
MO`4,9C/H?<'XW$4\'@N%,B7$V8U*K2I8?#QY:SJ3;:2]ZBTWJES72V/I3_@N
M;\<;'3?`WPX^`%A<QRZQXEUT?$CQ!(CIY>F>&O#UGJ>F:9!>1;B0;W6[X2P@
MCF'1)\89T<=-_P`$,_A#J7A/X2?$SXMZE9/;-\4?$EAI.A"ZCC29M!\%I=VS
M3I*(T+QRZUJ6IQ,0-DC:(TB*JNHK\>?#/A[XN?\`!3G]K[5;Q(Y;,^,M3@O]
M>U.#S=0TCX9_#33)Q!9"*67Y)O(TM8X;)3B*ZU&YBCFPMV"?[*OAA\./"?PF
M\`>$?ASX*TT:7X7\':%8Z%HEFSO/,EI:0JGFWEQ(`UU>.X=Y97^=Y979CN9J
M^2\5JN#\+?!_A_P6HXGVO%>;\N.SN,9)K#U).-2*C+JI<M*,+;JC4G+2HC]&
M\%,NQ_C1X_<5>/\`5PU3!<$</-Y?D/MXVJXE0C*DYQ6RIJ-2O*:UY77IP3O3
M;.]0`$$G+'"G&2,X!.#GU7]:L5"BJ,9))SGVS^7^<U-7\A1O>6MX.UGWT5V_
MG<_O^#DXISCRR>Z72^OY%.Y3<'.X99450V"N2[#[I&"3GOZ#TK^4O]H[]OK]
MN+1_VM?BG\%/A1\2KTQ6'Q(F\)>!O#5IX0\$ZA<2M<2P6FGZ;#=:AHHD:4W,
MG+22N<-@$<`?U9W:@JS9(P`QP#G"'/''/:OXK/CGXTTCX=?\%./&/Q$U]+W_
M`(1_P+^TG9>)=7.GVHO;N33-%UG2=5OXK6S_`.6TR1`\CG$A':OZ:^C-D.59
MYGG&L<?D=#B/$9?E%3$8;#8FFJD/;J6DDGI=VMV/XO\`IG<39YPYD/AS_9/$
M^,X6PV;9W##8^O@Z]2C.&!E!.<VZ<HMVWTU/H[QE^V#_`,%;/@-!:>,?BO;>
M+M%\."XMK1IO%GPM\$3>';B660>79W%]HFDL+>YDC^4(US&Q8_(^[`/[5_\`
M!.S]MX?MH?#;Q-?:SH>G>&_B5\.[S3M,\:6&CF=]%N[;6H]3;1/$.CI>L9K2
MQNVT?45:UDDF:WEL&5YFW+7YF?MK_P#!5+X+_'GX#>*O@A\+/!_C/7_$'Q+@
MT_1EU#Q%HUGI6GZ/`FIVES)?6MDU[<75YJIFMUBMBBK&5G.V8.H#_3O_``1K
M_9=^(GP+\!?$KXA?%'2KCPUKOQ>F\(3:+X5OMIU32=!\,V>MS+>ZG`29+">Z
MU#Q'=A(9OWBQZ>A(Y-?3>(V393B_"2MQ!QAP!@?#GC>GF%.CEM+!T?8RQ^%3
M@ZDYQ]L[<L7)ZPNK+0^%\(^),^P?CMEG"?`/BSFGC#X=XG+<77S2IC'5JTLO
MQ,8U5&*JU(7CR2C1Y6I6;J.CJXW/-/&W[&G[;>N?MTGXR:!XEOU^"(^.7A'Q
M:VFQ_%K6;6(^$=,U/1I];M6\+P7GDR1RVMK=?Z/LVL#M;J17[[6,C)8VVX2`
MI!$'66.1)58*,JZ2`-N!!'(!]?6OY>/BG^U?^T7I7_!3*3X2Z=\7_&-K\/!^
MT-X"\-+X,@OG?1)M`U34_"T5_I4T3H0EJ]OJ%RCKUQ,>>1C]>O\`@H3^VO%^
MQM\+[/4='ALM;^)OC>ZN]-\!^&[QI#:H+2&&;4/$NJ+:MO31K&.94=`-T]Q?
MVT2E>37P7'_"/B!G>+\),CQ&'P&-Q_$F4TGEU/`PY)4:+DDHX^R2E6L^>4T_
MAB[O0_3?"+C[PPX:R[QRXFR_%YI0R_AO.:SS:KF57VL:^)BI1MER<KPIW3C&
MG=;I^:_0MKZ0<JA)VE_+\MP2HX)5F*]._IBIX[DRX*E<$!LX*D#CC!)_G7\H
MGPE\'_\`!4S]M+0+KXO:-\:_$7AWP[J5_?+HMWJ7C>7X=:/JSVKB.4^%-&T.
MS(GT99L*DXS`Q!P20:Z+X$_\%!?VJ/V0OCL_P6_:[OM7\2^%+75K31O$TGB=
M[.ZUWPA9:@T45EXLT?Q2L*/KWAPLHE;S_E$)?GS%6C$?1[SEQS7!9+QME'$7
M%.04W4QV48:<OK5%05YQBY)*<X[-7^+1V=D:Y=]+7(Y8G(<9Q)X>YWP5P9Q-
M65+`9YF$8_4\3*5E!)1NXQG\46^EWJC]E/\`@HG^V[:_L8_"W2]9TC3].U[X
MD>.+R]T?P+HFI&0V"/86;7FJ>(-6@AECDN=,LU-HGDI+$]Q<:E!&KJ`X/X;_
M``T^*W_!7+]JZ+6/B%\+?$?CF^\-QZA+:)?:'=>"_!7ABVU"VO%2?3=/74K>
M'[;+%;MLD$:S>0R9E>0L<_6W_!<7X8>*O%?ASX&_''P_!+K/@KP;#XB\.^*[
MNQB^T_V5%XGDT#5/#NOI&AV-I=Q-IUS:M(FX&XU"PP1M-><_\$[_`/@J?\(O
M@Y\(_!_P'^-.BZOX63P7)<6>C>.-'TZYUS19]-O;JYNA+K]O;;KBROXKN[N!
M-)"LY92I-OU8_IO`/#M')?!##<9<$\"X+CKC3%YA.GCUBL/''5<)"$IQ5)89
MJ\;QC!.*O*2DZ]^6*BOQ_P`5>*ZW$_TB\9P+XA^)&9^&'ASEN`PN(RJ>!Q%3
M`4<?B:L:$KU,?3:4.?VE5MRYE^[C17L7+F?WM_P38U[]N?4-9^,'AG]L:+Q7
M#;^%[;P5'X,'BK0=&MYK^[U4^(VUF6Q\7:1;>1XDLX(-,TS")<3/$U\3*Q#Q
MA?UA`*3`HI)"LH8N"#DY"XY(("G`X&"?08\\^'7Q0^'GQ4\*67C#X;>+]!\7
M>&M0B=[/6O#UY;7EC'M"EXYGC;%O<QH06@D"S!4^[@\_A_\`\%1/^"D'Q#^%
M7C>;]GCX`:D=#\4Z59V$WQ`\;VMN+S6;2_UC,VF^$_#D<UNT5I?M:/";FZ7=
M,J:C'Y($B;3^"X'AKB'Q>\0<5@<GX=PG#N:8R#KU\+3H^PPN"AAH)8BK*G%<
M\4WK9*4KNRM&[7].XGB[A/P!\)<%FN=<68[C#+,*_887%8BLL3C\?/$MSH48
M5E)TYM+2,JDU%)7;O:_]`*W6`W?;*$!VE<9ZY8MAFW`\9'TZ$_FM_P`%-/@-
M\?\`X_?"WX?^'/V?=7N])\4Z-\1%U?7KFT\7:AX)23P^?"_B>Q>$:A:2JTR_
M;;NR(3<1N&2.@K\IO"'[*7_!77Q=X2L?B5:_&'Q7I.H:K8#7-,\.>*_BEK-G
MXD4RV[W-I'J.AQPBVTN:4W$1-HXWP[%CE(D#`?<?_!6;XL_&+]GS]FWX$W?P
MZ^(_B3P[XIE\?Z;X8\0^*M-N`FJ^(+>T\!^)9+I]3EC3]_YVH:;;W+XX,B`C
MCK];DOA[4X9\1N!\OX3XYR7BW/\`$UY4^:E#$2PF&JJG+FAB8U8*,TK--1YK
MN_F?#\2>*=+C7PF\1,PXV\.,_P"">$\)@,-6C*K.A#%XBE4E!\V%E1DYP;;3
MO*RMZGW/^PQ\./B9\(?V;/`G@?XO:E)J?Q!T7^V&\07$NNR^)I))-0UN]OK-
MY-:GF=[K%E-`#EL@D#C`K[`-T-VT.A/`*C@].<$\$YQQG\:_.7]A?XWZK=_L
M'>&?C;\:/%E[KLFB:#X_\2>*/%>LR^?=OI?AC5_$$DMU<W$QP%ATJP5$+$(`
MBAB%W&OQOT[]H']O/_@I+\9/%^A_`3Q=JOPL\!>&DFO#8Z;K,OAC1_"VA3W-
M[:^''\8:]I:27.I>)-1%I?JMO'B(G3)YK;,43&O(P_A9G_%G%G'E7,LZR_A[
M+^&<;BEFF95>:&6T&L34BHT(QUO-V5.*3]VRMJD_:J>-G#'A_P`"^$^#R'A_
M->+<WXXP.$CDV54YT99EB*?U>$I5\3.K-62][GF[IN+VU/ZKEN,YX7CKAE8@
M<??"GY3R>.>.>]+YS#);'3("AF./7@=/QK^4;Q3\;/\`@H)_P3>^+'@2W^,G
MCZX^*/@OQ*6G33]1\13^*O#OB72+&>SM_$6FZ7J6I0+>Z/KMLUYI;*Z)*8S-
M&'5DOL+^QG[</Q[UI?V!==^/7P4\5ZIX=GUW0?`?B/PKXBL";+4[73?$FLZ&
M7B;J;6X^S74\$T9YC;?&V&!KASKP?SO*\RX,P^"S?!YYD?'V)6#R[-<.Y/"O
M$N48NG5NDXM74FM[7ZW2]?ASZ0V0YUE/'V(S#A_&Y!Q%X;T)8K,LHQ'(\8L-
M&/,ZE)P;A+6ZNFUMW/TI:X9`'+1A`N69]T2@@@$EF!P.O;K@4U+EV.-HS@MC
MU7=\K``\J0>OM[U_(Y^SC^TU_P`%%/VH=,O/V?OA-X_US4-?FU6]\4^*OBAK
M6K_8=8T/P_+;:9IMAH$^L3V<J>%[5M1M-0FC$4,MW//<2VN$2%WKEO'_`,</
M^"@?[`GQJT32OB5\5/$6OW36=GXFBTC6?%4WCCP5XVT%YI;6]MK:747C-I<(
M8&5WCB1HI760$JK!OM5]&CB26:YCPW_KID\.+,)3EB:66N<_;U\+"-W.%E92
M>K2=WRJ[BMC\Y?TQ^'O[&R?BS_B'F>1X)S"K#"U\V;PWU;!8B<U#V6(49RDY
MPOS2<>B>CU/[$A-G<,'*@$X!X!QD'/7O^=0-=2*'^0,59E488D[0IQ@@;CSV
MSUKY-\:?M6>"O!W[+T?[4U_)>#PE=^`]'\<:5I0*-J%[-XBTVVOM%\/NH!)O
M7NKB.UD9,JN99\$(*_G!\(?'C_@HO_P4)^*OB&S^&/CGQ!X1TO3U;4;K3/"O
MB6;P?X%\":;<3RMI^E:EXDMK;.I7FQ'C@D=OM-\8'EVI%MQ\)P-X1YYQ=A<[
MS;'9AA^&.'>':CI8O,L;[7ZK2J\T8>S:I1E)RO*[72V[;2?Z=XD?2"X:X#Q7
M#F1Y;E6+XUXMXJA1K8+*LO\`9?6ZE"I:5.M)U)**IXB',Z=M6HMV2/Z\(KMW
M5"RJ"?O\D%3AB!M&><#N13Y+K;N`*@H<$G`!^A+`=?\`/:OR9_8%^!W[9/P2
M\6_%&\_:D^+%UXT\)CPCID?A-9_'L_BW3[?5%NKV]UW4B;ZP@N+!XK&VM%\R
M0$>7<MMSV_-+XC_MD_M?_M\?M%ZE\(?V3O$]]X,^'-I)K/\`8-SHM\_A>XO?
M#NCW/V74?B#XIUZ6!KB/2KDW>D&UMEC1;07<(+O+>QXWRSP@QF><09[EV2<6
M9=C^'>&J,<1CL[3JQP%*A+55(^TBIN5[QY;:\K['+GOC_AN&N%.'<VXAX&S3
M+>+N,,56PF7<.OV4LQK8BG4Y>1.G)P47%JS>MW:VNG]2$=S(Q8.@X(4$!R0<
M9^9=N%&".=V,$58:4J"3@!0"20>0<=,=\5_*#\6-7_X*7?\`!/+5O!GC[QG\
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MW)"X.XC<`&Z].<=*_DF_9VTS_@I)^WPWC+QSX/\`VB]6T73]`UB#3M2GO_&&
MJ^#M.;5+Y4U"2STKP]X4L]D=K#;SQ(F"8.!AB1Q^Z?\`P3\^%?[4_P`*?#/C
MW1OVHOB+)\0-4N==TUO!-U_PDLGB.&+0;;28([V6.:[LXKB%WU"3<XD+`EP1
M[WQ]X48?@'#XJGC^.LLS#B++:JHXC*L.L5]:HR?+=SE4IQIM*[?31:=@\+_'
M;&^*..RV>6^&><93POFL<54H9OB985X2K"E+ECRJ$W-7=TM+IZ:ZL_0!U9T+
M+\Q:/8`<XSD`@EJ_+C]O/_@F]X2_:EL9OB)X*:T\#_'K2(K>32_$D8>UT_Q7
M'8-OM](\3_9&5S)A46VOU/VBUQM4F)F2OU0\ML*,KQ]X8.">>U-,).`-H`8%
ML[CD`'`_[ZP?PK\XX;XESKA'.,)GF0XR>`S'#SC*7+%3I54G'FIU82TG3E9<
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M%?X:?\$MOC%^R?\`M1^!/C#\`O'&@>,/`FGZV+7Q#H7C6[DTCQ1'X3UL&S\1
MVPN;'2C:ZS/#IL<#VTOR3O./WJ!?F;^F\)XN9'QI#Q/S'/<2N'N(^)N'*&6T
M*4G4J8>=:BY5)K"U;/V-.;5.U&?+%2E)J4C^+,R\!^*/#BMX,93D&73XTX1X
M4XMQ>;8F=-4J6)HX;$5*,:*QL'**Q=6FG*:Q--1M"FZ;IWFF?5/_``5[\42>
M&?V*/'UM92F&3Q3K_@KP\0A.#$^OPW<O(_A=+.)?;;G@"O$O^",GA>U\`?L<
M>._B?=VX5_%GC?Q9XAN)`A69]&\%:);Z):VN6ZH)M+U>1>.NH'`.*\*_X+6?
MM.:3>>&;']EM/!OC&SUT>)/"_C*7QAJ5D-/\(:C906MXJZ=HM\LC2:EJ"WEQ
M`9%,:)$%.\@XS[=_P3!\?:;XL_X)S^._!VER*?$WP^L_BGH.L6"N(YH)=>TO
M5_$NA7&R0@^1/;:H468X4O;2+N/EFN6ED>:Y;]&?#*>$FL-Q#Q+@JF(E%J?-
M0DIT:-27))\D9U8Q5IV<6DVDK2._$<0Y3G'TQ,RJPQBGC.&>$<11HIQG!^WI
MP]O6II3C&[I4YRO->Y*TE&3::/S._P""/UC<_$+]NN]\;:Y_IVLV?@_XC>/=
M4EE"D?VGX@O;/3=2N`?XMU[XJE'&2?-SR`2/8_\`@N9XGOO%G[0GP/\`A?I`
M^UW/AOP+<WEE:*RL'UCXB^*5L3%(&(R[1>$-*QR!B9,D5Y]_P0PD%M^U/X]$
MN"J_L_>(=[R'$H>'QS\.%<E6.Y2S&0\X.%.1GBNL_:_L#XT_X+&?#S0-00RV
M5MXU^`]EY$[#RGM+&+1->N8D5R0T+)#-(0!R)).YK]BS6I1H?24S'-)\M2CP
MAPM*O1BK-Q=+!3222V?[^:^5C^?LFA4J_0^RO*Z=XXCQ#XU^H5YM:-3QE--N
M7PNWL8+>WXGNO_!576=*_9W_`&)_V>OV3M*O/.UC4[;0AJ$D4!$<N@?##0+6
M36M8E16)CFO?%=SI$D:@%WWW@P,`-]N?#KP5_P`,R?\`!+'5]-N+(Z3K&F?L
M\^,_%FKVB*HFM/$/C+P[J.MS6DHC)!N8I=8B@;DKNBZG!-?DC_P46\2GXV_\
M%.O`'PJOC]I\.>&=<^#_`,.([,,1FWUW6].UKQ0P#':KR+K13)QN%L@;@`U^
MZW_!1*=M._8>_:&FC=(I!X)2PP&5?,CO=;T:PDMHNF<V\\JJ.I5@#SFOQSB/
M#U\#POX&\+8QREB./,T_M[%\UXRG+$XNC2H;V33A*3;OT3>EV?T!P=7PF:<:
M_23XPP25+">&F1T.&LM3=O9T\%@,3/&5(KXK5)TTTTK.SM?2_P"-G_!"+X<M
MJ/Q1^.'Q7N%!7PGX+T'P79!D5I+B[\9:O_;^JR^9G"SQV_@K34.3TU$8/#8P
M[JU;XQ?\%LWBF#7MEX2^**2A6*E!%\+_``9]KL223D"+5+2,^[2#;GG'U1_P
M0<CMH_@M\<+M6C>ZN/BKI%M.RX$BQ0^$;)K9)@V"$\V:?:/<GO7S9^PLW]N?
M\%>/CWJ-XFZ2R\3_`+0DB/+R\<MOXIU#0XA'G[K"TA?DD`IQGT_1N)<QJU/%
M#Z2N<5*BY\AX>6&H)--J&(CA8)JVR;C)I[;ZV/RGA?)Z'_$&_HE<-PC:GQ3Q
M;''XB33BF\'5Q$Y[VNTFM-9=$FUIS'_!;*]OO%_[6WPG\`Z9/(+ZV^&WAO2=
M-4<K#K'C/QCKD,%TH)Y=)K:R/IC';FOM?_@L=I&D_#+]AKX1?#7PW;K8>'M'
M\>_#KP'I5N`<6^A^$_"'B%=/A(`Y6+3]$A[<C@`GBOA;_@I+XBTFP_X*A?#O
M4/$5Q'#H?A;5?@$VL/,I,<&D1ZQI&KWTDA&0L2PWTS-G`'G`DXR:^]_^"Y=J
M^K?LK_#&ZLY8I0OQU\-30M$ZM'<1:GX)\=6<#6[J=L\8>;>2I*F,[P2,5YN!
M]LL9]$7*XQE#!5Z>*K<ZA)Q>(JU:2<;Q3?,FDTM%[UT[:GJYS*&*P?T[,W:=
M/-*6(P5%\UU_LD744+725I*[T=UHG;8]M_8[^`7A[XM?\$R?AE\)-?-Q::%\
M0_"4E]K9L&B666.]\;3:_>6^V1"&29M.BADR>8KN4=<9^3/^"Z/CS2O"_P`(
M/@9\#]*@@M!K'B;4_%DEK9QQP6NG>'?`&C+HVE6/V>-0L5L]SXB)A"C`&B.H
M`.T5]X?\$OOBMX(\=?L<_"71/#GB&PU+6_`F@?\`".>+=)ADVZAH.KVVI7DT
MEI>VC`,F89HG#*"A69#GYJ_$?]N2'XD_\%#OVQ-3\,_L\>$M:\=Z'\--,'PR
MM=>M[.XL_"=O>Z1JVIWGBC4]5\27JK8V4(U:^N8"IF^U/'9(P@*[2?DO#W`8
MBMX^\0XWB.O_`&;P]P;F.=9IBIXAJC1A4J^VIT74J5.6*=1PH\EV[I75E>_W
M/BQF>7X;Z,7"N6\)X)YMQ/XD9+D&1X:CA8NOB)T::HUJD84:2E.U/VE9ST7*
M[*33L>K?\%`?$\WPI_X)V?L2_`&.*:SUOQOX;\.>,M;LC_H[_P!G^'/#%OK6
MMVMZ&&Y;A_%7B[32,='M7/&TD?!_[.7[.W[4O[:^B^%/A+X7GO[7X+>`=5U&
M^77-6@?2_`'AV\UC4;K4-1UD16D,?_"7>*I?[5N4@7]].JPRB>:*!G63^F>S
M_88\&_&/P#\$3^U[I6@_%/XJ_"C0WTQM2T2^\0Z1X1N'N+J.40W.B66H6]OK
M3BSLM,222>$JYMR/)\L@'[?\*>"]`\%:/8>'?#&BZ/H&@:1`EII&CZ)I]MI6
MGV%FK&000V=E$D2*)6<C8BYW?-D\G+"^/N7<'<(8K(>&LBIYKQ?BLTQN.JYI
MB5&>'ISK5L0H5<''XN;V55<LI1A9;QW1T5_HI9UQ[QOA^)N,>(:F2<'X+*LH
MR[#95A7RXFI@L+A</[;!XN:]RG3^M4Y3J4(.<6F[2O8^>/V5OV3OAK^R;X!C
M\%?#O3)[B\OI8;OQ=XPU)8#KWB_58D<_;]3G2,&.W22XG^S6Z$10(=JC)9F^
ML85*11H2254+EOO-CC<W)RQZGW-(L(4``D\D\D_>^OI4B@A0#R1Z?7WK^8,R
MS',,YS/&9QFV,GF.8XZ<IU*U76J[V]V]O@2BK*^EDDK)6_MG(\DRKAS*\%DN
M1Y=3RG*,!3C3H86BE&C0C'2T%IK)^\WU=WNW=U%%%<AZY4N2!C/`P3^7KQ_G
M%?Q=?%;0=%\6_P#!5+7O"WB/3[75_#WB7]J31]$UK2K]7:#4-.U;Q'H>GW]I
M*J2)OA>W<G`+8VG(Q7]H=T0?EW#<5.U.`3@C)!8@=2,\C&:_E0_:*_8`_;FU
MG]KCXI?&WX5?"V]:UO/BC<>,_`GB6S\7^"]/N(_(GL+FQODM[_7!+')]HMGX
MDB7H"`0>?Z4^C1G&2Y7F_'5/-L_PW#U7,\HJ8?"XC$5H48QKRE>,>:35I+>]
MU;>Y_&'TS<ASO.LA\.,1D_"N-XKIY)G4,3BL-@\+6Q,W0C%*4W&E"5XOX;:W
MVM8_3#]KW_@FW^R$?@!\3O%/A?X>Z+\+?$W@GP5KWBG1?$GAN>ZTTVVH:)I-
MUJ-O87]G>7CPW=I<W$"Q&)E#LTR^6=X7=\1?\$1/V@/B/J7Q%\6?L]Z_K%[K
MG@&U^']WXT\+07UW?7K^%K[3-:T+29=.T@WS,]CHL]MJIE>'*;9A&/+!5@/)
M/&7[*7_!8+XUZ='X)^)EQXKO?"FH&`WVG>)OBMX.BT"1496=M1MM#U;S;N)6
M0,L;1SKO53M!&X?K7_P3G_X)_K^QWI?BCQ=XWUC3?$WQ>\;6B:=?W>CH[:3X
M7\-6MS+?)X?T6[DAC-V;FX2QGO9)`N9]-C$9,8S7U6?YGDW"G@_Q3PKQ=XEY
M?XC<1YYC*<LKI83$PQ\L%*,X-UO;UG.I!.*:]R<6WM'WFG^?\'95Q)QMX]<#
M<:<">$&8>#O"_#E.O_;5?&819<LQI3:Y:,</0I4E5E*5I)2B]FW9I)_AO\:#
MN_X*],_:3]J;X:NH'\(;7/!QQCMSD_0U]#_\%V;?5Q\>?@K(58:._P`)=433
M6D7RHFU6#Q;>G4_+D;`E9;66R\[!(A6Y@:78)HB_3?$[]B#]J;Q!_P`%'Y?C
MIHWPGOKSX7K\??!/C(^)QXC\'0Q-H&BW_A^ZOKU-/N/$"W3!8]+G7;Y.YB1@
M8SM_7?\`;R_8MT7]L[X3V_AU;^V\.^/_``E>7&K_``]\626\4Z65[=VIM=2T
MJ_=4=Y-#OECMA=QQ@EC86S[2T*U]%CO$O@[(>./`/.<5CX9EE&29&L%F/U::
MG4PM6I!QM+EO:=-R4I+LI==#X_)?!SCCBWPU^D_PU2R7$97G.<<33QV`6+HU
M*"QE*EB*U9>SC4C&4X5:;M&237-*)U'[!USX=O/V.?V<&T(P/9I\*/"ME<PP
MDRE-8M+)+?6FD"#*G^W5U$OD84W&2<5^`?\`P7%OM!N_VH_!=II$]J==TWX,
MZ;_PDWDRV\<\5Q<:]XJO-)WR;\@K8OO`(V[9-Q((JWX%^&__``5__8_TN_\`
MAK\)_"WBC5_!UQ/=7&GCP[9^"?B/X0BN[Y99[G4-`;6D>_T&%KR1IE@EE@A5
MPIY&0WH_[.O_``2\_:2^//QIM?C9^VA+<Z9I-UJ]OXD\2Z%K^L6.M>,?'4]L
MMH;'1-4BTF66STGPRWE31RPH87MX7:"%")&)Y>"<GX:\+N/\^\6,U\0<MS?A
MRFL56P6'P>(Y\RS!XIRY:%6E96<.;][S6U5[VO;UN/>(>,_&GPNX9\$\C\)L
MXR3BF+P.'QU?'X2='*\O6"5*$L12K27*XU/9I1<+VIRJ*SE:_P"YG[,.C+JO
M[)WP&\-^.=/6^;4/@A\/[#7M&UVRCFAO;>?PKIEO/I^J:=J$#*^^W9(YHIDR
M%!&`RMM^!/VHO^"/'P!^(>FZ_P"*_@\LGP>\?0VEY>:5I^GRL_@+4KRSM+AH
M;"^T6<D:5!.<)+-9,C+&G$8`Q7L/_!2OX??M<>+O"OPI'[(K:U;ZQX0\47NM
M^)4\->*M-\,:DUE#HMUI6BVD2:I?0PWUF\M_?EXRI^>W@R=J';^0GBNX_P""
MU/Q2T"X^&?BGPU\6KK1=6@;2=6B32?`'AE;BR-K);7-IJ7BS0IK$WME,'`D:
M.\#,`2)BQ(K\]\,\DXGQ&(7'7"GBKE'!7UW&598S!XG&PHUJ5&=64OWF$E[M
M=<M[<UGRM62OS'ZEXP\2\(X'!R\-.,?!K._$&64Y=0P^!S#"X*I6I8BM4P7L
M:TZ6*BN;#N$E%3<6US-M.5K'G?\`P1Q^+'C#PK^U?H/P^TS5=1;P;\4=)\16
M_B7P\LI?2GU#2=!GUC1-;6Q`'V36(7T^XMSQG[&4[`UP?QIGL-,_X*H:W=>.
M4QHT?[3'A2[ULWD3QP1^'1XATB>T>0NHQ;I8NLF022DBE<AUS^OG_!,G_@F=
MXJ_9T\4W'QM^-=UIJ_$$:+J.C^%?">B:DNHV/AU-;AMX-5UC4M2@MU6;7?LP
MO+2(P/)&EM>L=PD.T9G_``4P_P""8/BSX^^+4^.?P).E2^.[RVM[+QEX,N[N
M'1#XFDLXW2TUW2=:G(2+6C;0V%K(DSQ1B+38)(W\Q6!_8\3XJ>'$_''B25#,
M:.$RCB3(Z64U\X3<*$L;.'+4Q2DXKEBJ35!R:Y>:%[V9^#8?P1\6H?1RX3^L
M937S#.N#^)*F=X?)96J5_J$(4:,,.E&4K-RI2Q"PT')6FF]59?N+;75O(SM'
M-"0%#S`<8+IO1F?.%&W&"3C'2OPZ_P""\;[_`-GGX,R'&#\:86R""-H\">,S
MD'/(VX/TZ5\9^%?$'_!;3PMX<@^%FD>$OBB;+2XCI5CJFHZ-\.-7OK>SM@\0
MAM/&6ISO)*8TV"WN&G9"K@"-65G/V]_P4$_9W_:8_:)_8T_9=\$:%X,O_&OQ
MF\+W/@G6/BE8SZ]X:L+VVU>+X7ZOI'B34+R\U?68(;B8^)+[:XCD8L\^Y05R
M1^0\%<&8+PN\4>!,YS?C/)\TROZ_67M\+BZ=65/#QHU?9UL1RM^QISYDH\SE
M9V4FGO\`NWB-XD8[QF\$_$_A[(_#SB#*\WCEV&?L\=@JM-U\3]8P_ML/A%9N
MJZ:4I6BDW%-Q32;.`^'R:K_PXV\0_P!CF87,?@KQ5(\D+R)/%IEO\3O/U-O-
MCYAA33(;MI78B...)GD(16(_,_\`X)^^"/VX_%^B?$6']C[XCZ3X'L],U3PV
MWC?3KO6=)T>^NIKS3K]-"O6AU'1;AS:&UM+N-94>.)RF?+;`=?Z+?V&?@7XB
M\&_L2>$_@3\<O!#Z9J%QI/C7P_XP\)ZC/8:A')I'B/6]:6>TGGTN[EB>.?2]
M0.&20X$F>HQ7X[^(OV!OV\OV)_BQJWQ#_8]O;OQ]X?N7NK6TNM+NM$O]:O/#
M,MQ)=VVC>,O!VLW5I%KI@=I`7A=C)+Y4J>5M9#]YPAQSP_B/^(S\&TLURC"Y
MQG.?SS/*ZN:TJ=;*\<O;Q4J->;?*Z?)"-2'2\^97<6C\P\0/#+BF%'Z/?B%4
MR3/,7D?#O#M#*<VHY+.KA<ZR]QH.7MZ$8Q]KS\]25.5+EUY+.RDF3_&']@O_
M`(*F_M`:9I6A_&7QMX/\=Z9H>I3:MHT.L>+;"%-/NY[62TN[JWFTW0X)))3!
MY:?,QCPQ)'6OKK]HGX9>-/@Y_P`$?[GX7_$3^RQXK\(Z-X:T[61HUTE_ITH_
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MCGUBNM6U:0=L7V.H->%?\%[XXE^*/[.LX7$LO@;QZCL?[D.O^'D7..I+,/\`
MOD5]W?\`!(3]GCXR_LW?#+XKZ!\9O!4_@[5_$/CS2]6T>R?5]`U=KW38?"]A
M82W*OH6J7*H!<HXVL0WR$XV@D>-?\%@?V4/V@OVD/'GP1U;X,?#NZ\96/A?P
MKXTTW7)X];\-Z.MC>ZKKF@W=C"_]NZO;&7?!:SL"@8#RSZ''7D?%&00^E9G'
M$L\\P]+(*GUEPQDJL51E?`M0]]M*TII13VN<V=\&<23^@SDO#%'(<34XBC##
MJ6"]E)8F+_M&4I7I64DXTY<[NKI.YQO[6UO?W/\`P1F^`#Z>CO%!X<^!S:D5
M0D"U^QO"I=^B*9YHEYZM(HZL,][_`,$*)_#LGP)^,]G:RV;>*+?XMI>:O$F'
MNDTS4?!NB1Z*;F)?FA)%E?@*P#AHBK*#@'[R^&W[-H\;_L)>`?V;_B_HXTJX
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M`:<D7F&19F\*:E'$\,:_/*`Y3E`<EMHR2`?X[_V!/#/[5/BSX@^*M(_9,\9:
M3X)^($?@Y+OQ%->ZAIVEW>H>'AJNF&]M;.XO])N#/''JQL)C&,.5F$@W*&-?
MNU^P;J__``4@\;_&'Q!K/[8.A:]IGPMN/AIJVA:-I^NV'@+P_HEUXGO-9\/S
MVI/ASPP8KF:X&D6.MPM+<1*`-0`2+&XK\>_&[_@FY^U1^S7\;M4^-?[$-XVH
M:3)J&J:KHN@Z#JFGVGBSPQ:ZJTD^I^&CI^M^7:^(_#S7,J11PS&?;;VT*E!(
MH==?"C%9/X?T>//#7-^(,@Q>?YWAL!7PE>NZ6,R2KB82;JX;$U4[1C#XN6UN
M=MJ4M&X\<LOSCQ3J>&'BWE7"G$V%X:X>Q.8X;&X;#*IA.(*%&2BZ6/P=&2U5
M?F:4HR;Y5RNVJ(_BU^Q;_P`%:?CAX6;P;\6/B/X0\;^%%U*QU>32=5\7Z+%;
M'4--,S64I,/A^)_,0W$C8$@/R#`Y&?N+X`?L"^++G]@O7?V2/VA+FQT>^OO%
MFN:MH&I^&+\:\NAB75X==T/5TDN`BR/'J\5V#`7(\BY*Y&\*/C"Y^(O_``6T
M^+-O%X+C^'^J_#^.>'[)J?B>R\-^#_`%P+-BNXGQ!J.N3#2)0&D#2V*L[HJE
M($8L[?IW\1_`O[6GAK]A;PUX#^&.J76M_M,:%X?\$6M]KFGZ]8RW&HZM8:M9
M77BRY35/%-VBWZ267VU0TS*9&D&`H(4>1QOG?&N`PW#'#=?BCA'*G5SG#XFB
MLDE"$<%.$G_MTY07LZ=**=G92FUKRZ-'H>&O#OA]F.9<;\7X7@CCWB&6&R3%
M8;$U.)'72S.E42:RJC3E%5)U79R32]G&3^*^_P"&7CC]A_\`;Y_8.T_Q+\4?
MA?XXNG\(:.J7GB/Q#\+?$MQ"@TBT9=FN>)/!^L6C-?0P1,[2$QW7V1-S)A5:
M1?U>_P""4W[??C/]JM/&/PU^+BZ?<_$?P-HEAXFTWQ%I&G#3+?Q-X6O;N/3+
MR75-/@FDBM-8M-1FTY-ZE5NDOFE2-2DE?`7Q%\3_`/!:'XO>"-6^#?B?X1^(
MK;2?$]D=&\1ZEI?AGP%X?O-9TRXB,-[8:CXDBUG[*EA<(2+DV<-JY0L@8H[*
MWZ)?\$M/V`?$O[)=MXT^('Q3GTQOBIX\TK3M"CTG2;\:A9^%?"MK.NK7&FO=
MQPHESJ-SKTIDG,?F111:;:QQ2?ZP5]/XFYAE&-\,LUJ^)>9<-9QXB2Q$893B
M<BKTJF*K14H.53%\B2</9J:UL]=(IV1\SX*Y;GN5>,?#^'\)<KXMR3PI=/%3
MSC!<08:I1PF%G43Y:>'=1+5RY91:O^\YW>:;9^P=%%%?Q>?Z0A5;RT5W*Y!=
M]S<X!/`;@C&21R>O%6::R*WW@#R#^(Z5,E=QDHJ4X:QNVDGMT\FQ.[3CS.*>
M]OO_`#/./'WPJ^'GQ.T.3PY\1/!WA_QMH38_XEOB73;76+:%_*>#SH([R)S;
M7.QV'FQ[)<G[YKXAU+_@G%\*O"WACXQZ'^S]XF\7_`+4/C)X:A\.:ZWAO5[S
M6/"<$4%^;Q+JW\):S=&*VNY(KC4K222UN;65;36;F.%T)CV_I,5!ZCJ,?A33
M&C=5SR#U/4=#P:][*^)N(,EA"CEN;5\/A%4I5GAW4<\-[6A/VE*H\/*]&<HS
MU3G!Z)+:Z/DL]X$X3XEK_6LYR+#8C'.G5HO$JFHXGV5>'LZL%7AR58J4%;2;
M7]W1'\]/[&O_``3S_:A_8R_:5T/QXA\!?$;X=:MIFJ>!/%NJ:1KUUH^LVGAG
M6;BSO#KQTK7-.C%U<07>CVKRV_G,2MP_E/)A6'QI^U.?VI;C]O63]I>']F+X
MK6-GX'\?>%[CP_!9>#M8\0Z?K_A[P.T5A9WS:QH,=U:AM5LK><KY-PXC@G6-
MBLJ-7];Y@A)SY:9#;@<=#ZCTY].M(;>$LS&-=S`!B,@L!NP&P?F`WMC/3<<5
M^MY?X^9^N*\;Q?Q+D&`XIS7,<K>45W.$L)SX5SNY-T/^7O(Y0YN6UK+8_!\V
M^BMPO/@W+.!N%>(\PX4R3)LZ6>X:*G'&2IXQ0LHKVZC^[51*:5[WN]7O_*-^
MW[\'?BYIOQV\%?MV?"SX;^,K[P9XV'PY^(WEZEX=O8M9\!>+/"XTTG0/'6@1
M;+K3;2[73;8&7(1"\B_:=S1J//\`]HG_`(*-?M*_MJ>"/^%$^&_A!::5::YJ
M&EQ:YI'@&U\1^*?$7BB]L;Q;J+26EDAACTG3)=02U,JR0DQ_9U#WT:EF/]?(
MMX%SMB1<JJ$J-K,B@A49ARR`$X!XYIB6=I&I2.VA12,$)&J[AW#$#YAZYZUZ
M&4^.V!PN!X<I9UX>X+B/-.#8.EE6,Q&)K\^&IJ5X)TTG";II)1V5US)1V/$S
MSZ+&9XO'\7?ZN>+&8\*\/^(E9XO/,#0PM";Q6+:2DZ.)E*-6A0FG44J,4U:2
M5VKH_G&_X)Y?#C]JO]ACQKXU\*?$KX+>(M:^'?Q2^'<WCJ._\+*/$D?A[QGX
M#T;6-8T[0[J6Q,GV35KW3;B]LYH)8Y7>YL]/^RR2JTBS?%O[*-I^V)X3_;*L
M/V@[']G/XLRR>./B+XHU3Q[I3^`/$.G:4/#_`,0=9OKOQ#!'?:K!#%;_`&!-
M2+0%IGP\*F978.M?V&+:VZ`A(44'`PH(`"[=H`!PH&Q<`=,<4XVT!!4Q(5.,
MJ5!7(;>#MZ9W$G\:Y?\`B/..JXOCG,<3P?ELLP\0,#1R_'3@JBBZ%&E4HQ<8
M2<K3<90;][XJ<7<[O^)5<)0PGASEF`\2,VPV5^&F/KYC@82A0J3=7$5:-6=.
M4GRJ,.:G-)I-J-22MJV?RV?ML?L#?ME_M(?M:?%'QQH7PQT^?P;KFI:=IWAW
MQ-JOC3PUIMA<Z#I.A:1I]D9;)M2EOK.4W`NPPDMHP?LT6Q002_W7JO\`P3E^
M,GQV_9>^!/P+^/GQUM?#][\*-?U;4KG_`(1G1/\`A*UUC1S92:1X/T^YU?5;
M[3C_`&CI.B7%_9^<8+B*5)XSY9E0S/\`M0;>$\&-?O%^^=Q));.>#DFE$$*G
M*QJ#G/&1SDGL?4FO%Q_CGQOB\NX2RS"1PF34N"/9O+ZN&I?OJ<Z5+V$9MU>>
M-Y0<G/E23DHNSZ?29/\`1@\/,OS7C7-<QQ&99^_$!U/[4P^)Q]58/$*I76(?
M/AZ:BI2A.,53;G[L+Q5NOY[?LF_\$Y/@)^R/K%WXQ\(GQ;XG^(&I:=-HE_XR
M\3ZV)6?2KAEEFL+;0M)M+6PM[3S=Q4O!/,NX_OS7V]X=\-^'_#%O+8>&O#^C
M^&[![FXNY-.TC3;'2[1[RZD,US?-;Z?"B2RRR$L[E=S-DMD\GK1&@SA0,]<#
MVQ31!".D:]"O_`2<D?3-?F&<Y]GG$>88K-<]S2KF&8XE<DJM2;FY03NKIV4;
M?RQ?+?4_:.&^#N&N$,LPF2\,Y%ALERO`-SHT</#V:IU&DI--\SDJB5IN3<K)
M)7LDE6,#!)+$<C=@@>R@#`QCCC/O4E'2BO+/IPHHHH`****`*=P?WBY_N$?<
M8_*S`L-PX`.T9XZ?G3'B#C(W$`EB=JG.23CG&.I_"KC11N=S*"PZ'G(^G-.V
MKC&./2H49*;DY*2?1PB]/7=_,F45+?7T<H/_`,"C+7[D4@(F3:FX8/"XVC/K
MRH'6HD@W.P90%XVJ!C/(R-V3N!&01W!J^(HUY"@?G_C3RJG.0.>O%*,;<RY(
MQATBN5KU^!-?(3A%RYU%*?=I2>EK6DTI)Z;K;\3$MK2.VN6\H1(&)8JJ/NR>
M"`S<*,=>W?KS6CY89"&^9<<DX()/X9)'3M5G8N,8&*`BCH`.,?AC'\JU?*[W
MYI.2LVY-O[WJA^_S<SJ2DV[MRDYROM9-K2-KZ+9F(\4:NQ6,Y9@S$1%RQ'W<
MLS=/8\?I4MK$RL"LT@4ECM=6XR<X#,3@#G'/&>E:C0QN"&4$'KR?Z&G*BH`%
M4`#H.N/SJ/9TK)<CO'9N<GV[^FP37M))SY[+6_MIO7_!:UO*Y4,8,BN22R;@
M".@!(R.F.<?X8--`R6$@0JQZ<'IT!XY&/7GGK5THI.2.>>?KUI<#T'Y"IY9<
MW.JDHR6]N5*7F_<?ZBY79KW97[INWDO>T^21"J`#"C:`>><YZYR3U&0:9/&D
MH"-G:#_#D'.",@KR#S5D@'L.:0HIP"!QS^7O5\JO*37-*6]_^"G^0.+M&,6J
M<([):?DU^91,"X*Y94*!"5?Y@`&&X$I][+`YSU0'M@PSP@QMLRH^?;M7<I\P
MH[;E5>N],_4GVQJ;%]/U/^--,4;=5!_/_&H<)=:DJJZQERV:[744TOO]"735
MG%12B_Y7*$D_YE)-M/S6OF9ULOE0$9/!RQV,,X]0?F8\T_RQ(%8EV((96^Z5
M."-RAUX.">GK5_RTQC''U/U]:!&BY(7!/7D_3UHE3BTDH145:T7%222Z)Z.Q
M2A&R37,DOM.4I-]W4NI?@9_D*0P+2LS98,&`(/3"NH_=L0>2,$X`/'%1B%71
M_.A+')*J&#MEL@X9!E.YSGKCO6H(HP0P4`@D@]\GK0T:,-K+D=<$G_&FH6<;
M<ONVM[BO'_"[Z?.[\PA'E6C<9O[7--N/I>7O?.W8SXXMD)0K+MSQ'*ZY49)`
M4D<+C`'H`*F>`.JA28VZDJ%+'@@#[O4`\$_K5GR8MH78-H)(';)ZTX(HZ*.!
M@>P]!Z"E.G&7,G"Z?7FDI/;XG_P_S&E+FYIM3FOMN*O+_$OA^X@13DC!((;.
MXJ=P(Y!`'3/\_2HVB0G.,D)MQPJD$8Q\H^OYU;VKZ4;%]!TQ^%-1;2N_9-?R
MV=O-.4=^E[;=2?9WLIOG5[MM;_W;)I<OEY+0IB&,!%`967&PJ=Q4*-H&6&2.
M>_//%.DC&WYAN;MN5F*YXR!VJUL7T_G_`(TFQ",;1CTJ72C*W,E4[N48R;^:
M42TY*+CS:=$FXV7:]V_T\C*,$#E3(DFX#Y)%,L?EE"2"C*V8SR>1C.<'BG)`
M)-RR^85)8G$R-G))!`5<KCH.]:0AC!!"`$`@')X!Z]Z7RTY&T#/7'&?RINF[
M1BG'DCLG33Y5VBW+3\=2>5R</:>^ELW*;E'R3NN;U:78J,BNNU5XSRC,Z`<G
M[H!P!P0?4'!R,BGV\(C8D$DE2",18R2O0QQKCA0,#CCIGFK(10,`<?4_XTH`
D'3^M/D]Y23<?[MHN/R;CS+Y-%)2Y8J4N9QZV<;^MI-/YG__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
